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De thesis… het langverwachte boekje… een weerspiegeling van een meer dan vier jaar durende 
periode als doctoraatsstudente op het labo Farmacologie – LIPIT na de naamsverandering. Een 
bijzondere en verrijkende periode die succesvol kan worden afgerond dankzij een solide 
wetenschappelijke begeleiding en een hartelijke entourage, dit laatste zowel op het werk als 
daarbuiten. Daarom wil ik dit boekje heel graag beginnen met een woordje van dank aan een 
heleboel mensen. 
 
Achter iedere doctoraatsstudent staat een promotor. Marc, de afgelopen jaren is er volgens mij geen 
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om te luisteren naar zowel kleine als grote vragen en problemen en wist je met je wijze raad en 
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gemaakt in het onderzoeksleven en je hebt me gestimuleerd altijd positief te denken, een niet 
onbelangrijke eigenschap in een onderzoekswereld die vaak gekenmerkt wordt door ups and downs. 
Ik heb jouw goede begeleiding en niet aflatend enthousiasme enorm geapprecieerd. Dit is een zeer 
mooie bagage die ik kan meenemen naar de toekomst. Bedankt! 
 
Paul, tijdens mijn onderzoeksstage in het vierde jaar farmacie kreeg ik in jouw labo de 
onderzoeksmicrobe te pakken. Ik ben je dan ook heel dankbaar voor het vertrouwen dat je in mij 
stelde om hier een doctoraat te beginnen met jou als copromotor. Je kritische ingesteldheid en 
zinvolle suggesties hebben mede bijgedragen tot het succes van dit doctoraat. 
 
Ik wil eveneens mijn oprechte dank betuigen aan de juryleden, Prof. Dr. Wim Annaert, Prof. Dr. Marc 
Espeel, Prof. Dr. Ludo Van Den Bosch, Prof. Dr. Ida van der Klei en Prof. Dr. Hans Waterham, voor de 
kostbare tijd die zij aan dit werk besteed hebben en voor hun waardevolle opmerkingen. Eveneens 
hartelijk dank aan de voorzitters van de examencommissie en de doctoraatsjury, Prof. Dr. Jan 
Eggermont en Prof. Dr. Mathieu Bollen, voor hun interesse in dit proefschrift. 
 
Een doctoraatsonderzoek zou uiteraard niet mogelijk zijn zonder geldelijke steun. Daarom wil ik 
graag een woordje van dank richten aan het Agentschap voor Innovatie door Wetenschap en 
Technologie in Vlaanderen voor de specialisatiebeurs die mij werd toegekend en het vertrouwen dat 
gesteld werd in dit project. Dit onderzoek werd eveneens mogelijk gemaakt dankzij de financiële 
steun van het Fonds voor Wetenschappelijk Onderzoek - Vlaanderen (Onderzoeksprojecten 
G.0237.04 en G.0754.09), het Bijzonder Onderzoeksfonds van de K.U.Leuven (GOA/2004/08 en 
OT/09/045) en de Europese Unie (project ‘Peroxisome’ LSHG-CT-2004-512018). 
 
Op de vraag ‘wat vind je belangrijk in een job?’ zal ik steevast antwoorden ‘een goede werksfeer’. Ik 
prijs me dan ook enorm gelukkig dat ik dit de voorbije jaren heb mogen ervaren. Bij de start van mijn 
doctoraat kreeg ik een plaatsje toegewezen in het assistentenlokaal – of beter de ‘ladies-room’ – te 
midden van een enthousiaste ‘vrouwenbende’. Ilse, Helena, Mieke, Elke, Erin en Patrizia, ik wil jullie 
bedanken om mij als jong kuiken onder jullie vleugels te nemen en mij de weg te wijzen in de grote 
labowereld. De deugddoende pauzes en plezante buiten-labo’se activiteiten zal ik nooit vergeten! 
Een doctoraat wordt gekenmerkt door een tijd van komen en een tijd van gaan. Zo heb ik elk jaar 
met spijt in het hart van één van jullie afscheid moeten nemen en werd onze meidengroep stilaan 
kleiner en kleiner. Het laatste jaar waren we nog maar met z’n drietjes – Erin, Patrizia en ik. Patrizia, 
je verhalen over Italië, je lekkere espresso en je zonnige persoonlijkheid brachten me vaak in 
zuiderse sferen. Bedankt voor de mooie tijd die we hier samen hebben beleefd. Erin, waar zal ik 
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beginnen? Al die jaren stond jij klaar om te helpen met eender wat, en altijd met een glimlach. Dat ik 
tot op het einde van mijn doctoraat op jou heb kunnen rekenen – de tijd die je hebt willen maken om 
dit werk ettelijke keren na te lezen en me te helpen bij alle praktische en administratieve 
beslommeringen die een thesis met zich meebrengt – bewijst dat jij er eentje bent uit de duizend! 
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twee nieuwe collega’s kunnen verwelkomen. Oksana and Serena, the next generation of this lab, I 
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1. PEROXISOMES 
1.1. SMALL ORGANELLES WITH MULTIPLE ROLES 
Peroxisomes are small subcellular organelles that harbor a variety of essential metabolic 
pathways in virtually all eukaryotic cells. These organelles, originally called ‘microbodies’, 
were described for the first time in mouse kidney cells in 1954 [1]1
 
. In 1966, de Duve and 
Baudhuin proposed the term ‘peroxisome’ referring to the central role of this organelle in both 
the production and removal of hydrogen peroxide [2]. To date, the organelle family of 
microbodies comprises several peroxisome-like structures including glycosomes in the 
parasitic protozoa Trypanosoma and Leishmania, glyoxysomes in plants, and Woronin bodies 
in filamentous fungi. Although the morphology of peroxisomes significantly varies among 
tissues and species, they are typically characterized by the presence of a proteinaceous matrix 
surrounded by a single limiting membrane. Peroxisomes are mostly spherical with a diameter 
ranging between 0.1 and 1 µm, but they may also appear as elongated, tubular structures [3]. 
Since peroxisomes, unlike mitochondria, are devoid of DNA, all peroxisomal proteins are 
encoded by nuclear genes. In addition, virtually all these proteins are synthesized on free 
polyribosomes in the cytosol, and posttranslationally imported into the organelle [4]. 
Peroxisomes play a major role in lipid metabolism. Interestingly, peroxisomal functions differ 
considerably according to the cell type and the organism. One of the most conserved 
peroxisomal processes is the β-oxidation of fatty acids [5]. In eukaryotic microorganisms and 
plants, fatty acid β-oxidation is an exclusively peroxisomal process, whereas in mammals this 
pathway is confined to both peroxisomes and mitochondria. Although peroxisomal and 
mitochondrial β-oxidation share a similar mechanism, their substrate specificity and 
physiological role are distinct. While mitochondria β-oxidize the bulk of fatty acids derived 
from the diet, peroxisomes catalyze the β-oxidation of a more complex set of compounds such 
as bile acid intermediates, very long chain fatty acids (VLCFAs), long chain dicarboxylic 
acids, and pristanic acid [5]. In mammals, additional peroxisomal functions comprise the 
α-oxidation of 2-hydroxy long chain fatty acids and the 3-methyl-branched fatty acid phytanic 
                                               
1 References of chapter I and VII are compiled in the reference list on p.135. For the other chapters, references 
are listed at the end of each chapter. 
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acid, the detoxification of glyoxylate, and the synthesis of ether phospholipids such as 
plasmalogens [5]. Reactive oxygen species (ROS; e.g. H2O2), which are generated as 
byproducts of peroxisomal oxidative reactions, are mainly removed by antioxidant enzymes 
(e.g. catalase) within the organelle itself [6]. This well-conserved H2O2-based respiratory 
pathway has lately become an issue of great interest because of increasing evidence pointing 
towards a connection between peroxisomes and cellular ageing [7]. 
 
1.2. PEROXISOMAL DISORDERS 
The importance of peroxisomes for human health is underscored by the existence of a wide 
variety of genetic diseases associated with peroxisomal deficiencies (Table 1 p.6). These 
inborn errors of metabolism can be classified into two categories: (i) the peroxisome 
biogenesis disorders (PBDs) resulting from a malfunctioning of the entire process of 
peroxisome assembly, and (ii) the single peroxisomal enzyme deficiencies (PEDs) affecting a 
single peroxisomal metabolic pathway [8]. 
 
1.2.1. Peroxisome biogenesis disorders 
PBDs are a heterogeneous group of lethal hereditary diseases caused by mutations in PEX 
genes, encoding peroxins, i.e. proteins necessary for the proper formation of peroxisomes. 
Within the PBD group, two broad clinical spectra can be distinguished [9]. The first one is the 
Zellweger spectrum comprising cerebro-hepato-renal syndrome of Zellweger (ZS; 
OMIM 214100), neonatal adrenoleukodystrophy (NALD; OMIM 202370), and infantile 
Refsum disease (IRD; OMIM 266510). Common to all three are liver dysfunction, 
craniofacial dysmorphism, perceptive deafness, eye abnormalities and variable neurological 
impairment. Even though characterized by similar symptoms, the three phenotypes within the 
Zellweger spectrum clearly differ in severity. Patients suffering from Zellweger syndrome – 
the prototype of PBDs – display the most severe phenotype and usually die in early infancy. 
NALD and IRD patients present with milder clinical symptoms and have longer life 
spans [9,10]. The second PBD spectrum is rhizomelic chondrodysplasia punctata type 1 
(RCDP type 1; OMIM 215100), a disease that is genetically, clinically and biochemically 
distinct from the Zellweger spectrum. Typical symptoms are severe skeletal aberrations and 
LITERATURE OVERVIEW 
5 
 
profound growth and psychomotor retardation. The most severely affected children do not 
survive the first decade of life [10]. 
 
To date, the PBDs are classified in 13 autosomal recessive complementation groups for which 
all the responsible PEX genes have been identified [8]. In most cases, fibroblasts from PBD 
patients are characterized by the presence of ‘ghosts’, peroxisomal membrane structures that 
are larger in size but less abundant than normal peroxisomes and can be seen as peroxisomes 
lacking their matrix content [11]. Differential diagnosis of PBDs is based on clinical findings, 
measurements of VLCFA and plasmalogen levels in blood and urine samples, and is 
confirmed by clinically available biochemical or molecular genetic testing [9]. 
 
1.2.2. Single peroxisomal protein deficiencies 
In contrast to the PBDs in which nearly all peroxisomal functions are disturbed, the single 
peroxisomal protein deficiencies are characterized by the loss of a single enzymatic process 
caused by a genetic defect in one specific peroxisomal protein [12]. To date, a dozen of PEDs 
have been identified of which X-linked adrenoleukodystrophy (X-ALD; OMIM 300100) is 
the most common one (incidence: 1:17000). The molecular defect of X-ALD is due to 
mutations in the ABCD1 gene encoding the adrenoleukodystrophy protein, an ABC 
transmembrane transporter involved in the transfer of very long chain fatty acyl-CoA esters 
across the peroxisomal membrane. Hence, the subsequent breakdown of these compounds by 
peroxisomal β-oxidation is no longer possible. The disease is characterized by a broad 
phenotypic variability ranging from late onset adrenal insufficiency to rapidly progressive 
childhood demyelination [13]. 
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Table 1. List of peroxisomal disorders 
 DEFICIENT 
PEROXISOMAL 
PROCESS 
DISORDER 
DEFECTIVE  
PROTEIN 
MUTANT GENE 
PB
D
s 
Formation of 
functional 
peroxisomes 
Zellweger spectrum  
(depending on the type of 
mutation, the patients manifest a 
Zellweger syndrome, neonatal 
adrenoleukodystrophy, or 
infantile Refsum disease 
phenotype)  
Peroxins PEX1,2,3,5,6, 
10,12,13,14,16,
19,26 
Multiple peroxisomal 
functions 
Rhizomelic chondrodysplasia 
punctata type 1 
Pex7p PEX7 
SI
N
G
L
E
 P
R
O
TE
IN
 D
EF
IC
IE
N
C
IE
S 
α-Oxidation Refsum disease Phytanoyl-CoA 
hydroxylase 
PHYH 
β-Oxidation X-linked adrenoleukodystrophy Adrenoleukodystrophy 
protein 
 
ABCD1 
 Acyl-CoA oxidase deficiency Acyl-CoA oxidase 1 
 
ACOX1 
 D-Bifunctional protein deficiency D-Bifunctional protein 
 
HSD17B4 
 2-Methyl-acyl-CoA racemase 
deficiency 
2-Methyl-acyl-CoA 
racemase 
 
AMACR 
 Sterol carrier protein X deficiency Sterol carrier protein X SCP2 
Ether phospholipid 
biosynthesis 
Rhizomelic chondrodysplasia 
punctata type 2 
Dihydroxyacetone 
phosphate 
acyltransferase 
 
GNPAT 
 
Rhizomelic chondrodysplasia 
punctata type 3 
Alkyl-
dihydroxyacetone 
phosphate synthase 
AGPS 
Glyoxylate 
metabolism 
Hyperoxaluria type 1 Alanine:glyoxylate 
aminotransferase 
AGXT 
H2O2 metabolism Acatalasaemia Catalase CAT 
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1.3. REGULATION OF PEROXISOME ABUNDANCE 
1.3.1. Introduction 
Peroxisomes are highly dynamic organelles that can rapidly modulate their size, number and 
enzyme content in response to varying environmental conditions. This characteristic is very 
prominent in methylotrophic yeast species such as Hansenula polymorpha and Pichia 
pastoris [14]. Peroxisome proliferation is massively induced when these yeasts are grown on a 
medium containing methanol as a sole carbon source since peroxisomes harbor the key 
enzymes for methanol metabolism [15]. By switching the carbon source to glucose or ethanol, 
the induced metabolic activity of peroxisomes is no longer required and redundant 
peroxisomes are quickly and selectively degraded (this process will be described in more 
detail in section 3.3.). The ability to rapidly change from a basal to proliferative state and 
back, renders methylotrophic yeast species very attractive model systems to study the 
biogenesis and degradation of peroxisomes [14]. In other yeast organisms, namely 
Saccharomyces cerevisiae and Yarrowia lipolytica, peroxisome proliferation is observed 
during growth on fatty acids, and oleic acid in particular [14]. 
 
Similar to yeast species, the unique feature of induced peroxisome proliferation also exists in 
mammals. For example, treatment of rodents with a variety of xenobiotics, collectively 
referred to as peroxisome proliferators, initially leads to a transcriptional upregulation of 
peroxisomal β-oxidation enzymes, followed by a significant increase in the number and size 
of liver peroxisomes, and marked hepatomegaly. Chronic administration of these compounds 
to rodents can even result in the formation of hepatic tumors [16]. Typical peroxisome 
proliferating agents in mammals comprise hypolipidemic drugs (e.g. fibrates), industrial 
phthalate ester plasticizers (e.g. di-(ethylhexyl)phthalate (DEHP)), and several types of fatty 
acids [17]. 
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1.3.2. Mechanism 
Both in yeasts and in mammals, peroxisome proliferation is organized at the nuclear level. To 
date, two transcription factors, namely methanol expression regulator 1 (Mxrp1) and 
methylotrophic peroxisomal protein regulator 1 (Mpp1), have been identified in P. pastoris 
and H. polymorpha, respectively [18,19]. Baker’s yeast cells grown on medium containing 
oleic acid as a sole carbon source induce the expression of a distinct set of fatty acid 
β-oxidation enzymes as well as proteins involved in the expansion of the peroxisomal 
compartment. This process is mediated by an oleate response element (ORE), present in the 
promoter region of most of the target genes, which is bound and activated by the transcription 
factor complex Pip2p:Oaf1p. In addition to an ORE, the promoters of several responsive 
genes contain a type 1 upstream activation sequence (UAS1) which represents the binding 
target for Adr1p, a transcription factor triggering the expression of a number of genes 
involved in the metabolism of different carbon sources [3,20]. 
 
The biological effects of peroxisome proliferators in mammals are regulated by peroxisome 
proliferator-activated receptor α (PPARα), a member of the steroid hormone nuclear receptor 
superfamily [21]. In response to ligand-induced activation, PPARα forms a heterodimeric 
complex with retinoid X receptor (RXR) and subsequently binds to peroxisome proliferator 
response elements (PPREs) initiating the transcription of target genes. By modifying the 
expression levels of enzymes associated with β-oxidation, transport, and uptake of fatty acids, 
PPARα plays an essential role in maintaining lipid homeostasis, particularly in liver, kidney, 
and heart. In addition, two other PPAR subtypes, PPARβ and PPARγ, have been described. 
PPARβ is ubiquitously expressed and has been implicated in the regulation of fatty acid 
metabolism in muscle, whereas PPARγ is mainly found in adipose tissue and is especially 
involved in adipogenesis, lipid storage, and glucose homeostasis [22]. It is well established 
that peroxisome proliferator-induced hepatocarcinogenesis in rodents is mediated by PPARα. 
The resistance of human liver to the carcinogenic effect of peroxisome proliferators is likely 
due to species specific differences in PPARα [23]. 
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1.3.3. Medical significance 
Peroxisome abundance – which is controlled by organelle formation, half-life, and 
degradation – is of great physiological importance. Whereas the number of peroxisomes in 
rodent hepatocytes increases upon treatment with peroxisome proliferators, some cell types 
completely lack peroxisomes. The latter involves mature reticulocytes, lens fiber cells, and 
male germ cells in which peroxisomes – and other organellar structures – are degraded as part 
of a physiological differentiation process [24,25]. The number of peroxisome remnants in 
cells derived from PBD patients is also significantly reduced in comparison to the number of 
peroxisomes in wild-type cells. Furthermore, peroxisome abundance has been implicated in 
the process of cellular ageing. The presence of antioxidant defense systems as well as 
ROS-producing enzymes within peroxisomes, highlights the key role of these organelles in 
the production and breakdown of reactive oxygen species [23]. Disturbance of the strictly 
regulated balance of ROS generation and scavenging leads to ROS accumulation which 
consequently gives rise to oxidative stress. By inducing modification and destruction of 
cellular macromolecules (i.e. DNA, proteins, and lipids), oxidative stress initiates the cascade 
of age-associated cellular deterioration and may lead to several pathological conditions [7]. 
Whether defects in peroxisome morphology and/or metabolism are cause or consequence of 
cellular ageing is still controversial. Interestingly, it has been shown that senescent 
mammalian cells have increased numbers of morphologically altered peroxisomes which are 
compromised in the import of matrix proteins, the H2O2-degrading enzyme catalase in 
particular [26]. Accordingly, an elevated frequency of age-related diseases has been observed 
for hypocatalasemic individuals [27]. In addition, both in plant and mammalian cells oxidative 
stress induces pronounced elongation and proliferation of peroxisomes via the upregulation of 
PEX genes. Moreover, peroxisome proliferation seems to prevent ROS production in 
hippocampal neurons and to protect from β-amyloid neurodegeneration. Finally, the defensive 
role of peroxisomes against oxidative stress is emphasized by several findings indicating the 
absence of peroxisomes in a number of human cancers including breast cancer, colon 
carcinoma, hepatoma, and renal cell carcinoma [28]. 
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2. PEROXISOME BIOGENESIS 
Proteins specifically required for the biogenesis and maintenance of functional peroxisomes 
are encoded by PEX genes and called peroxins (abbreviated as ‘Pexp’, and including a 
number corresponding to the order of discovery) [29]. Currently, 32 peroxins have been 
identified in various organisms and 16 of these are conserved in man (Table 2) [30]. 
Peroxisome biogenesis can be conceptually divided into three key processes: (i) assembly of 
the peroxisomal membrane, (ii) import of peroxisomal matrix proteins, and (iii) peroxisome 
division. Most peroxins are required for the sorting and translocation of peroxisomal matrix 
proteins across the peroxisomal membrane, while only three peroxins are known to be 
involved in peroxisomal membrane formation. 
 
2.1. ASSEMBLY OF THE PEROXISOMAL MEMBRANE 
The assembly and maintenance of the peroxisomal membrane requires both recruitment of 
lipids as well as targeting and insertion of proteins into the lipid bilayer. The phospholipids 
phosphatidylcholine and phosphatidylethanolamine principally constitute the peroxisomal 
membrane [31], nevertheless peroxisomes lack the capacity to synthesize these compounds. 
Since the endoplasmic reticulum (ER) is the major site of phospholipid biosynthesis within 
the cell, a lipid and/or membrane flow from ER to peroxisomes has been suggested. The 
following paragraphs will focus on the current models regarding peroxisome formation, the 
involvement of the ER in peroxisome biogenesis, and the import mechanisms of peroxisomal 
membrane proteins (PMPs). 
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Table 2. List of peroxins 
Peroxins identified in mammals are depicted in bold. Table adapted and modified from [32]. 
Peroxin Characteristics and function 
Pex1p AAA ATPase required for matrix protein import, involved in the recycling of the PTS1-receptor 
Pex5p from the peroxisomal membrane to the cytosol 
 
Pex2p RING-finger domain-containing integral PMP required for matrix protein import, putative E3 ligase 
 
Pex3p Integral PMP required for peroxisomal membrane assembly, peroxisomal membrane anchor for 
Pex19p 
 
Pex4p Peripheral PMP required for matrix protein import, E2-like ubiquitin-conjugating enzyme 
 
Pex5p TPR-motif-containing protein required for matrix protein import, PTS1-receptor (and adaptor protein 
anchoring the Pex7p-PTS2 complex to the peroxisomal membrane in mammals, plants, and 
Y. lipolytica); in mammals there is a short (Pex5pS) and a long (Pex5pL) splice isoform of Pex5p 
 
Pex6p AAA ATPase required for matrix protein import, involved in the recycling of the PTS1-receptor 
Pex5p from the peroxisomal membrane to the cytosol 
 
Pex7p WD40-repeat-containing protein required for matrix protein import, PTS2-receptor 
 
Pex8p Peripheral PMP required for matrix protein import 
 
Pex9p ORF wrongly identified (represents the antisense sequence of Y. lipolytica Pex26p) 
 
Pex10p RING-finger domain-containing integral PMP required for matrix protein import, putative E3 ligase 
 
Pex11p PMP involved in peroxisome proliferation (mammals contain three isoforms (α, β, and γ) encoded by 
different genes) 
 
Pex12p RING-finger domain-containing integral PMP required for matrix protein import, putative E3 ligase 
 
Pex13p SH3-domain-containing integral PMP required for matrix protein import, member of the docking 
complex 
 
Pex14p PMP required for matrix protein import, member of the docking complex 
 
Pex15p Integral PMP required for matrix protein import, peroxisomal membrane anchor for Pex6p 
 
Pex16p Peripheral (Y. lipolytica) or integral (mammals) PMP required for peroxisomal membrane assembly 
 
Pex17p Peripheral PMP required for matrix protein import, member of the docking complex 
 
Pex18p Predominantly cytosolic protein acting as a co-receptor for Pex7p in S. cerevisiae 
 
Pex19p Predominantly cytosolic protein required for peroxisomal membrane assembly, import receptor 
and/or chaperone for PMPs 
 
Pex20p Predominantly cytosolic protein acting as an adaptor protein for Pex7p in most fungi 
 
Pex21p Predominantly cytosolic protein acting as an adaptor protein for Pex7p in S. cerevisiae 
 
Pex22p Integral PMP required for matrix protein import, peroxisomal membrane anchor for Pex4p 
 
Pex23p Integral PMP involved in peroxisome proliferation, growth regulation of peroxisomes in Y. lipolytica 
 
Pex24p Integral PMP required for matrix protein import and peroxisomal membrane assembly 
 
Pex25p Peripheral PMP involved in peroxisome proliferation, elongation and constriction of peroxisomes 
 
Pex26p Integral PMP required for matrix protein import, peroxisomal membrane anchor for Pex6p 
 
Pex27p Peripheral PMP involved in peroxisome proliferation, elongation and constriction of peroxisomes 
 
Pex28p Integral PMP involved in the regulation of peroxisome size, number, and distribution (S. cerevisiae) 
 
Pex29p Integral PMP involved in the regulation of peroxisome size, number, and distribution (S. cerevisiae) 
 
Pex30p Integral PMP involved in peroxisome proliferation 
 
Pex31p Integral PMP involved in peroxisome proliferation 
 
Pex32p Integral PMP involved in peroxisome proliferation 
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2.1.1. Models for peroxisome biogenesis 
Since their discovery, the origin of peroxisomes – and the peroxisomal membrane in 
particular – is a very controversial issue. During the past decades, this intriguing topic has 
been addressed by several research groups. This has resulted in two major concepts regarding 
peroxisome assembly (Figure 1.1.) [33]. According to the classical model of ‘growth and 
division’ [4], peroxisomes are autonomous organelles that grow through the posttranslational 
import of newly synthesized peroxisomal proteins and multiply by division of pre-existing 
peroxisomes. In this view, the ER is thought to be a source of membrane phospholipids solely 
needed for the enlargement of the surface area of growing peroxisomes [34]. In recent years, 
the longstanding paradigm of ‘growth and division’ has been challenged by a number of 
research groups who argue that peroxisomes continuously arise de novo from the ER via a 
maturation process [35,36]. Initially, de novo peroxisome biogenesis was based on the finding 
that in mutants lacking detectable peroxisomal structures (i.e. pex3, pex16, or pex19 cells) the 
formation of functional peroxisomes can be restored upon genetic complementation. During 
the last years, growing evidence for the contribution of the ER to peroxisomal membrane 
assembly during de novo peroxisome biogenesis has been obtained by a diversity of studies in 
various organisms. Treatment of H. polymorpha and plant cells with brefeldin A – a 
compound that causes the nearly complete resorption of the Golgi apparatus into the ER 
through inhibition of the GTP-exchange factor for the GTPase Arf1, a protein involved in 
vesicular Golgi-to-ER trafficking – interferes with peroxisomal protein sorting and leads to 
the accumulation of newly synthesized peroxisomal proteins in ER-like structures [37,38]. In 
Y. lipolytica, the PMPs Pex2p and Pex16p have been shown to be N-glycosylated, implying 
that these peroxins traverse the ER [39]. Furthermore, real-time fluorescence microscopy in 
S. cerevisiae has demonstrated that both Pex3p and Pex19p are initially sorted to the ER 
before maturing into import-competent peroxisomes, and that Pex19p is required for the exit 
of Pex3p from the ER [40]. Lately, evidence for the existence of an ER-to-peroxisome 
pathway was also obtained in mammals. In mouse dendritic cells, electron microscopic 
analysis revealed a connection between a specialized ER subdomain and a peroxisomal 
reticulum from which mature peroxisomes might arise [41]. In addition, by using a 
pulse-chase imaging technique with photoactivatable green fluorescent protein, Kim et al. 
have shown that peroxisomes can arise de novo from the ER in both normal and 
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peroxisome-less mammalian cells [42]. Moreover, these authors postulated that Pex16p 
regulates this process by being cotranslationally inserted into the ER and recruiting other 
components that are required for peroxisome biogenesis [42]. Finally, Pex3p has recently been 
suggested to follow an ER-to-peroxisome route in human fibroblasts [43]. Altogether, the 
participation of the ER in peroxisome biogenesis is generally accepted. 
 
 
 
Figure 1.1. Prevailing models for peroxisome biogenesis 
(A) Growth and division model. Mature, pre-existing peroxisomes divide by fission to form new daughter 
peroxisomes. Both pre-existing and daughter peroxisomes grow by the posttranslational import of peroxisomal 
membrane (black triangles) and matrix (grey squares) proteins. (B) Maturation model. A subset of peroxisomal 
membrane proteins (black triangles) is sorted to a specialized subdomain of the ER from which a preperoxisomal 
structure pinches off. Additional PMPs (non-filled triangles) and matrix proteins (grey squares) are directly 
imported into the nascent peroxisome resulting in the formation of a mature peroxisome. Figure adapted and 
modified from Mullen and Trelease (2006) [36]. 
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Whether new peroxisomes are formed by budding from pre-existing peroxisomes or de novo 
out of the ER, in both cases the ER is believed to provide the necessary lipids for peroxisomal 
membrane expansion. How this lipid transfer occurs, remains enigmatic. Specialized vesicles 
or transfer proteins might be required to carry phospholipids from the ER to peroxisomes [11]. 
Alternatively, lipids might flip from the ER to the peroxisomal membrane at sites of close 
apposition, a mechanism employed for the transport of phospholipids from the ER to 
mitochondria [44]. To date, the physiological significance of the two apparently contradictory 
concepts of peroxisome biogenesis – the classical growth and division model and de novo 
peroxisome formation – is still under discussion. It has been hypothesized that de novo 
peroxisome biogenesis represents a backup system to guarantee maintenance of peroxisomes 
in case the organelles are lost [3]. However, both processes might occur simultaneously and 
the predominating pathway might be determined by species-specific, cell type-specific, or 
environmental conditions. 
 
2.1.2. Import of peroxisomal membrane proteins 
As already mentioned before, virtually all peroxisomal proteins are synthesized on free 
ribosomes in the cytosol and posttranslationally targeted to the organelle. Relatively little is 
known about the mechanisms for sorting membrane proteins to peroxisomes. The currently 
available data suggest at least two mechanistically distinct PMP import pathways: (i) some 
PMPs are targeted directly from the cytoplasm to the organellar membrane (cytoplasm-to-
peroxisome pathway) [45], whereas (ii) others are sorted indirectly to peroxisomes by means 
of ER-derived vesicles or a specialized section of the ER, the peroxisomal endoplasmic 
reticulum (pER) (pER-to-peroxisome pathway) [35,42]. The targeting sequences of PMPs, 
termed mPTSs, contain all essential information for the proper sorting and insertion of PMPs 
to and into the peroxisomal membrane [46]. The currently identified mPTSs show a great 
diversity in terms of length and amino acid sequence. Moreover, some PMPs (e.g. HsPMP34 
and Pex13p) possess multiple non-overlapping targeting signals. Recently, it has become 
clear that mPTSs consist of two functionally distinct domains: a targeting element – in most 
cases a cluster of positively charged amino acids – which directs the newly synthesized PMP 
to the peroxisomal membrane, and an adjacent hydrophobic patch serving as a membrane 
anchor and resulting in the permanent insertion of the protein into the lipid bilayer [46]. 
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The peroxins Pex3p, Pex16p and Pex19p have been identified as essential factors for 
peroxisomal membrane formation since no peroxisomal membrane structures can be detected 
in cells carrying a mutation completely inactivating the function of these proteins [11]. Since 
many years, the biological role of the predominantly cytosolic protein Pex19p in peroxisome 
biogenesis has been a matter of debate. At present, the idea of Pex19p being a multifunctional 
protein is widely accepted. Several observations suggest that Pex19p acts as a PMP-specific 
chaperone that binds and stabilizes newly synthesized PMPs in the cytosol by shielding their 
hydrophobic membrane spanning domains [47]. In addition, the capacity of Pex19p to interact 
with the targeting signals of a broad spectrum of PMPs, together with the fact that Pex19p can 
transiently associate with the peroxisomal membrane, indicate that this peroxin functions as a 
cycling PMP import receptor [48]. However, for some PMPs the Pex19p-binding site and the 
mPTS can be physically separated. Based on these findings, it has been proposed that mPTSs 
can be functionally divided into two classes: class I mPTSs which require Pex19p function, 
and class II mPTSs which are sorted in a Pex19p-independent manner [47]. Until recently, the 
only PMP known to use the class II PMP import pathway was Pex3p, an integral PMP that 
serves as a membrane recruitment factor for cargo-loaded Pex19p at the peroxisomal 
membrane [49]. A second PMP that is also targeted to peroxisomes via a Pex19p-independent 
class II mPTS is Pex22p, a peroxin involved in a late step of matrix protein import with a 
topology similar to Pex3p [50]. Interestingly, recent work by Fujiki and coworkers has 
indicated that (i) Pex19p is essential for the peroxisomal targeting of newly synthesized 
full-length Pex3p in vivo, (ii) Pex16p functions as the docking factor for Pex3p, and 
(iii) Pex16p plays both a necessary and sufficient role in the selective targeting of 
Pex3p-Pex19p-complexes. Based on these data a new classification system for PMP import 
has been proposed: a class I pathway with Pex3p as the membrane receptor and a class II 
pathway with Pex16p as the anchoring site, both depending on Pex19p-mediated membrane 
docking. Hence, Pex19p-independent PMP import – originally called class II – is included as 
an additional class III pathway [45]. 
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2.2. IMPORT OF PEROXISOMAL MATRIX PROTEINS 
In comparison to the import of PMPs, considerably more progress has been made in 
understanding the molecular mechanisms underlying peroxisomal matrix protein import. This 
process includes the following steps [51]: assembly of the receptor-cargo protein complex in 
the cytosol; docking of the complex at the peroxisomal membrane; translocation of the cargo 
across the peroxisomal membrane through a yet unidentified protein translocon; and receptor 
recycling to the cytosol. Remarkably, peroxisomes have the capacity to translocate fully 
folded and even oligomeric matrix proteins. 
 
2.2.1. Receptor-cargo interaction 
The sorting of peroxisomal matrix proteins relies on two evolutionarily conserved 
peroxisomal targeting signal (PTS) sequences. The majority of the peroxisomal matrix 
proteins contains a PTS1, comprising a C-terminal dodecamer ending with the tripeptide SKL 
(or conserved variants thereof), which is specifically recognized by Pex5p [52]. Only a few 
matrix proteins possess an N-terminal nonapeptide (R/K)(L/V/I)X5(H/Q)(L/A) (with X 
indicating a subset of amino acid residues), called PTS2, for which Pex7p is the 
corresponding receptor [53]. In Y. lipolytica, plants, and mammals, the PTS2 targeting 
sequence is usually proteolytically removed once the cargo protein enters the peroxisomal 
lumen. The corresponding peptidase in mammals has recently been identified as Tysnd1 [54]. 
Both Pex5p and Pex7p are cycling receptors, bringing newly synthesized PTS-containing 
proteins to the peroxisome and shuttling back to the cytosol. Unlike Pex5p, Pex7p requires 
species-specific auxiliary proteins to accomplish its function. In mammals, the PTS1 and 
PTS2 import pathways are coupled since the long splice variant of Pex5p acts as an adaptor 
protein in PTS2 import. In lower eukaryotes, however, Pex7p-mediated targeting is 
Pex5p-independent and involves the unique accessory proteins Pex18p and Pex21p 
(e.g. S. cerevisiae) or the orthologous Pex20p proteins (e.g. Y. lipolytica) [55]. Alternatively, a 
limited number of proteins lacking canonical PTSs are still efficiently targeted to peroxisomes 
by the PTS1-receptor which either directly interacts with an internally localized PTS, or 
indirectly carries the proteins to peroxisomes as a complex with PTS1-containing subunits, 
the so called ‘piggy back’ mechanism [51]. 
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2.2.2. Receptor-cargo docking and translocation steps 
Subsequent to cargo recognition, the cargo-loaded PTS-receptors dock at the peroxisomal 
membrane by interacting with the docking complex which comprises the membrane-bound 
peroxins Pex13p and Pex14p (and Pex17p in S. cerevisiae). Pex14p is believed to be the 
initial docking site for the PTS-receptors [55]. The exact function of Pex13p (and Pex17p) is 
not yet clear. Downstream of the docking event, another set of proteins – including the 
RING-finger peroxins Pex2p, Pex10p, and Pex12p – has been suggested to be involved in the 
protein translocation step. The RING-finger complex and the docking complex are associated 
into a larger multiprotein complex, known as the ‘importomer’ [56]. In most yeast species, 
both subcomplexes are bridged by Pex8p. Nevertheless, little is known about the mechanisms 
underlying protein translocation across the peroxisomal membrane and release of cargo into 
the peroxisome lumen. At the moment, two theoretical models have been put forward to 
explain protein translocation across the peroxisomal membrane. According to the ‘transient 
pore hypothesis’ [57], the PTS1-receptor Pex5p itself acts as a pore-forming protein and 
contributes to a transient import channel of variable size which allows translocation of cargo 
proteins into the peroxisome. In this context, it is noteworthy that Pex5p alters its membrane 
topology during the protein import cascade, as it acquires the properties of an intrinsic 
membrane protein upon interaction with Pex14p [58]. Moreover, recombinant Pex5p has been 
shown to have the potential to insert spontaneously into phospholipid membranes [59]. An 
alternative model for the Pex5p-mediated protein import pathway, called the ‘monomeric 
translocator model’, has recently been presented by the group of Azevedo and coworkers and 
involves five major stages: (i) soluble cargo-free Pex5p is present in the cytosol as a monomer 
(stage 0); (ii) following recognition and cargo-binding, the Pex5p-cargo protein complex 
docks at the peroxisomal membrane (stage 1); (iii) Pex5p inserts into the 
docking/translocation module exposing the bulky part of its mass to the matrix and a small 
part of its N-terminal domain to the cytosol (stage 2); (iv) embedded Pex5p is 
monoubiquitinated at a conserved N-terminal cysteine residue (stage 3); and (v) the cargo is 
released into the peroxisomal lumen and monoubiquitinated Pex5p is extracted from the 
peroxisomal membrane in an ATP-dependent manner (stage 4) [60]. 
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2.2.3. Receptor recycling 
Once the cargo is released, Pex5p recycles back into the cytosol for further rounds of matrix 
protein import. Although no energy input is needed for receptor binding and translocation, the 
receptor recycling event (comprising the ubiquitination as well as the dislocation step) 
requires ATP [61]. This ATP-dependent extraction of Pex5p is catalyzed by the peroxisomal 
AAA (ATPase associated with various cellular activities) ATPases Pex1p and Pex6p. These 
peroxins form hetero-octameric complexes and are anchored on the peroxisomal membrane 
by Pex6p in a Pex15p- (yeast) or Pex26p- (mammals) dependent manner [62]. It has been 
hypothesized that binding and hydrolysis of ATP may induce conformational changes that 
could generate the driving force to pull the receptor out of the membrane. The export signal 
relies on the ubiquitination of membrane-bound Pex5p2
  
, which can be either mono- or 
polyubiquitinated. Importantly, the two forms of Pex5p ubiquitination serve different roles. 
Monoubiquitination depends on the E2-like ubiquitin conjugating enzyme Pex4p (in yeasts) 
or UbcH5a/b/c (in mammals) and is a prerequisite for the dislocation of the PTS1-receptor 
from the peroxisomal membrane. Upon attachment of one ubiquitin moiety at a conserved 
cysteine residue in the aminoterminal domain of Pex5p, the receptor is extracted from the 
membrane by the AAA peroxins. After removal of the ubiquitin moiety, Pex5p can start a 
new cycle of import [60]. Polyubiquitination of Pex5p primarily involves the E2-like protein 
Ubc4p and is believed to provide a quality control mechanism, called RADAR (Receptor 
Accumulation and Degradation in the Absence of Recycling), which is responsible for the 
removal of dysfunctional PTS1-receptors by proteasomal degradation [63]. Very recently, the 
RING-finger peroxins Pex2p, Pex10p, and Pex12p have been identified as the E3-like 
ubiquitin ligases required for ubiquitination of Pex5p. Pex2p has been shown to mediate the 
Ubc4p-dependent polyubiquitination whereas Pex12p facilitates the Pex4p-dependent 
monoubiquitination [64]. 
                                               
2 Not only the PTS1-receptor Pex5p but also the yeast PTS2 adaptor proteins Pex18p/Pex20p can be 
ubiquitinated [51]. Most of the work regarding the role of ubiquitination in receptor release has been done on 
Pex5p. 
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2.3. PEROXISOME DIVISION 
Peroxisome division includes cell cycle dependent ‘multiplication’ under basal conditions and 
highly induced ‘proliferation’ in response to external stimuli. Both peroxisome multiplication 
and proliferation involve a three-step event consisting of peroxisome elongation, constriction 
and fission [65]. Key factors for peroxisome division comprise members of the Pex11p 
protein family, a select set of dynamin-related proteins (DRPs), and DRP adaptor molecules. 
The Pex11p proteins have been shown to induce peroxisome elongation. In mammals, three 
Pex11p isoforms (α, β, and γ) have been described. Pex11pα is mainly expressed in kidney 
and liver and mediates peroxisome proliferation under induced conditions. In contrast, 
Pex11pβ is constitutively expressed in most tissues indicating its role in basal peroxisome 
multiplication [3]. The third isoform, Pex11pγ, has been suggested to fulfill a similar function 
as Pex11pβ. In yeast species, two Pex11p-related peroxins, Pex25p and Pex27p, have partially 
redundant functions to Pex11p [66]. Either single or pairwise deletions of members of the 
Pex11p protein family result in reduced peroxisome abundance and the formation of enlarged 
peroxisomes, whereas overexpression causes peroxisome elongation and an increase in 
peroxisome number [67,68]. However, their exact mode of action is not clear yet. Following 
elongation, the peroxisomal membrane constricts by a still poorly characterized mechanism 
which results in elongated tubular peroxisomes with a segmented appearance resembling 
beads on a string [3]. The final scission event is responsible for the fragmentation of the 
interconnected peroxisomes into individual spherical organelles and is executed by the 
coordinated actions of DRPs and DRP adaptor molecules. DRPs belong to the dynamin 
family of large GTPases that facilitate tubulation and fission of biological membranes [69]. 
Yeast Dnm1 and Vps1, and mammalian DLP1/Drp1, are DRP family members essential for 
peroxisome fission. Fis1 acts as a DRP adaptor protein by recruiting and tethering cytosolic 
DRPs to the organelle membrane. Other adaptors that have recently been identified include 
Mff in mammals, and Caf4 and Mdv1 in yeasts [65]. Interestingly, the DRPs as well as the 
adaptor molecules are shared by the peroxisomal and mitochondrial division apparatus [70]. 
Finally, in S. cerevisiae, Pex28p and Pex29p seem to be involved in peroxisome distribution, 
and Pex30p, Pex31p and Pex32p appear to negatively regulate peroxisome number and 
size [68].  
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3. ORGANELLE DEGRADATION 
3.1. AUTOPHAGY 
3.1.1. Classical autophagy pathways 
The term autophagy or ‘self-eating’ refers to the degradation of cytoplasmic components, 
including individual proteins, macromolecular complexes and even entire organelles, within 
the lysosome (or vacuole in yeasts). There are three major types of autophagy – 
macroautophagy, microautophagy, and chaperone-mediated autophagy – each differing in 
how the cytoplasmic substrates are delivered to the lysosomal compartment [71]. During 
macroautophagy (often referred to as ‘autophagy’), a portion of the cytoplasm is sequestered 
by a double or multimembrane structure, called the autophagosome, and degraded by 
lysosomal hydrolases upon fusion of the autophagosome with the lysosome. In contrast, 
microautophagy allows direct uptake of cytoplasmic material by invaginations of the 
lysosomal membrane. Chaperone-mediated autophagy – a process that only takes place in 
mammals [72] – involves the translocation of specific cytosolic proteins across the lysosomal 
membrane and requires both cytosolic and lysosomal chaperone molecules. 
 
Under certain conditions (e.g. nutrient depletion), the autophagic machinery is induced in 
order to provide the cell with essential building blocks that can be recycled from the 
lysosomal breakdown of unnecessary cellular components. In contrast to this random 
elimination mechanism, autophagy is also capable of selectively degrading unwanted 
structures such as damaged organelles. Notwithstanding the occurrence of induced autophagy, 
the process also takes place constitutively at low levels under normal conditions [73]. 
Altogether, autophagy is of great importance for cellular homeostasis and survival, while its 
deregulation has been linked to various human pathologies such as neurodegenerative 
disorders and cancer [74]. 
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3.1.2. Molecular machinery 
Yeast genetic screens have led to the identification of more than 30 ATG (AuTophaGy-
related) genes that are required for both bulk and selective autophagic pathways. In all 
subtypes of autophagy, about half of the ATG genes encode key factors for autophagosome 
formation, and their corresponding gene products are accordingly referred to as the core 
autophagy machinery [75,76]. Additional Atg proteins adapt this core machinery to the needs 
of the appropriate autophagic subtype. Whereas the core ATG genes have homologues in 
mammals, ATG genes specifically involved in selective autophagic pathways are poorly 
conserved [77]. The sequential stages of macroautophagy – fundamentally similar between 
yeasts and mammals – and the involved molecular components are briefly discussed below. 
 
 
Figure 1.2. Schematic representation of Atg proteins required for autophagosome formation 
(A) Regulation of autophagy induction involves the Atg1p subfamily (TORC1, target of rapamycin complex 1). 
(B) Assembly of Atg proteins at the pre-autophagosomal structure (PAS) during vesicle nucleation. (C) Two 
ubiquitin-like conjugation systems are required for vesicle expansion. See text for details. Figure adapted from 
Nakatogawa et al., 2009 [78]. 
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Induction of autophagy – Bulk autophagy is mainly triggered by a shortage of nutrients, a 
response which is negatively regulated by the protein kinase Tor (target of rapamycin) 
(Figure 1.2.A p.21). Under normal conditions, Atg13p, a regulatory subunit of the Atg1p 
protein kinase complex, is hyperphosphorylated in a Tor-dependent manner and shows a low 
binding affinity for the serine/threonine protein kinase Atg1p3
 
. In the absence of nutrients, 
Tor is inactivated resulting in the dephosphorylation of Atg13p. This allows Atg13p to 
interact with Atg1p leading to the upregulation of Atg1p kinase activity which further 
modulates the autophagic response [79]. 
Vesicle nucleation – Induction of autophagy leads to the formation of a cup-shaped 
membrane in the cytosol, called the isolation membrane or phagophore. In yeasts, the 
isolation membrane arises from the pre-autophagosomal structure (PAS), the initial site of 
Atg protein recruitment. So far, there is no evidence for a PAS in mammals but structures 
reminiscent of the PAS have been detected [80]. Interestingly, in yeasts all autophagosomes 
seem to arise from a single PAS, whereas in mammals the isolation membranes are generated 
anywhere in the cytoplasm [81]. As a matter of simplicity, the term PAS will be used 
throughout the remaining part of the paragraph. An ongoing question concerns the lipid 
source of the isolation membrane. Since the unique composition of this membrane, i.e. rich in 
lipid and poor in protein, it is difficult to determine its origin based on the protein content. 
Both the ER and mitochondria have been proposed as possible lipid sources for the formation 
and growth of autophagic membranes. The concerted actions of the core autophagy machinery 
at the PAS are responsible for the expansion and transformation of the phagophore into a 
mature autophagosome. It has been suggested that the kinase activity of Atg1p is involved in 
the recruitment of other Atg proteins to the PAS, forming a scaffold for PAS assembly 
(Figure 1.2.B p.21). A core Atg protein that interacts with the Atg1p complex is the 
transmembrane protein Atg9p. Interestingly, Atg9p is partially recruited to the PAS while 
another pool of Atg9p is localized to a peripheral compartment (i.e. mitochondria in yeast and 
the trans-Golgi network and late endosomes in mammals) [82,83]. The shuttling of Atg9p 
between PAS and non-PAS structures has been postulated as a mechanism for membrane 
delivery. The retrieval of Atg9p from the PAS depends on the Atg1p kinase function and the 
                                               
3 Recently, a family of mammalian Atg1p proteins has been identified (i.e. unc-51-like kinases 1, 2, and 3) [76]. 
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Atg2p-Atg18p complex [75]. In addition, the vesicle nucleation process is mediated by the 
autophagy-specific phosphatidylinositol 3-kinase (PI(3)K) complex consisting of the class III 
PI(3)-kinase Vps34, the protein kinase Vps15 (p150 in mammals), Vps30 (also known as 
Atg6p; Beclin 1 in mammals), and Atg14p (mammalian orthologue is called Atg14L or 
Barkor) [78]. The PI(3)K complex functions at the PAS where it recruits PI(3)P-binding 
proteins, such as Atg18p, whose partial association with Atg2p is essential for autophagosome 
formation. 
 
Autophagosome maturation – Downstream of PAS assembly, the biogenesis of 
autophagosomes further relies on two ubiquitin-like conjugation systems involving the 
ubiquitin-like proteins Atg8p and Atg12p (Figure 1.2.C p.21). In the first conjugation 
reaction, Atg12p is covalently attached to Atg5p by means of the E1-like activating enzyme 
Atg7p and the E2-like conjugating enzyme Atg10p [84]. The Atg12p-Atg5p conjugate 
subsequently interacts with Atg16p (Atg16pL in mammals) whose self-oligomerization leads 
to the formation of a multimeric complex. A second ubiquitin-like modification system with 
Atg7p as E1-enzyme and Atg3p as E2-enzyme conjugates Atg8p (LC3 in mammals) to 
phosphatidylethanolamine (PE), a major component of biological membranes [85]. Atg8p is 
synthesized as a precursor protein from which the C-terminus is processed by the cysteine 
protease Atg4p in order to expose the glycine residue that is essential for attachment of Atg8p 
(LC3-I) to PE. Consequently, lipidated Atg8p (LC3-II) localizes to the isolation membrane 
and the autophagosome. Both in vitro and in vivo studies indicate a role for Atg8p in the 
expansion of autophagosomal membranes, presumably by mediating membrane tethering and 
hemifusion events [78]. In the course of autophagosome formation, both the 
Atg12p-Atg5p-Atg16p complex and Atg8p-PE decorate the expanding phagophore. Their 
PAS localization depends on Atg9p and the autophagy-specific PI(3)K complex. 
Additionally, Atg8p-PE recruitment to the PAS requires the Atg12p-Atg5p-Atg16p complex. 
Upon completion of the autophagosome, the Atg12p-Atg5p-Atg16p complex is released into 
the cytosol, while a significant portion of Atg8p-PE is trapped inside the mature 
autophagosome during its journey to the vacuole/lysosome. This characteristic has made 
Atg8p as the most commonly used marker to monitor autophagy [78]. 
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Degradation – Upon fusion of the autophagosome with the vacuole or lysosome, the inner 
membrane of the autophagosome together with the enclosed cargo is degraded by 
vacuolar/lysosomal hydrolases. The intravacuolar lysis requires the putative lipase Atg15p. 
Delivery of Atg15p to the vacuole occurs via multivesicular endosomes suggesting that the 
fusion of these structures with the vacuole is essential to initiate the degradation of 
sequestered cytoplasm [86]. Although the mammalian homologue of Atg15p is currently 
unknown, fusion of autophagosomes with endosomes has also been reported in mammalian 
cells [87]. Eventually, the monomeric units (e.g. amino acids) resulting from the breakdown 
of macromolecules, are exported to the cytosol via vacuolar/lysosomal membrane permeases 
and the putative amino acid effluxer Atg22p [86]. 
 
3.2. SELECTIVE AUTOPHAGY PATHWAYS 
In contrast to bulk autophagy, selective autophagy is characterized by the targeting of specific 
components for vacuolar or lysosomal degradation. In the last few years, several types of 
selective autophagy have been reported in yeasts and mammals (Figure 1.3. p.26). The current 
challenge in this field is to decipher the various targeting operations and the molecular 
mechanisms responsible for removing specific cell structures in response to diverse stimuli. 
 
3.2.1. Non-organellar types of selective autophagy 
Cvt pathway – The cytoplasm-to-vacuole targeting (Cvt) pathway refers to a biosynthetic 
process that transports certain resident hydrolases such as aminopeptidase I and 
α-mannosidase to the vacuole through a selective autophagy-like mechanism [88]. This 
pathway has only been identified in S. cerevisiae and P. pastoris. 
 
Aggrephagy – The breakdown of toxic aggregates by autophagy can occur in a selective way 
and is referred to as aggrephagy. This phenomenon seems to be of great importance in the 
context of proteinopathies, i.e. diseases characterized by the accumulation of aberrant protein 
aggregates such as Huntington’s and Parkinson’s disease. In cell and animal models of these 
disorders it has been shown that autophagy prevents neurodegeneration by eliminating the 
aggregated protein structures [89]. 
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Ribophagy – In the budding yeast S. cerevisiae, it has been shown that – under 
nutrient-limiting conditions – mature ribosomes are both non-selectively degraded by the bulk 
autophagic pathway and rapidly and selectively degraded by a specific macroautophagic 
process, termed ribophagy [90]. During extended periods of starvation, ribophagy seems to be 
essential for cell survival implying that the selective removal of excessive, non-functional or 
wrongly-assembled ribosomes may be required to attenuate protein synthesis and to provide 
an important source of new building blocks to maintain cellular homeostasis. Interestingly, 
ribophagy requires an intact autophagic machinery but is independent of proteins that are 
needed for other selective autophagic pathways [90]. The ubiquitin deconjugation enzyme 
Ubp3, and its activator Bre5, were identified as essential factors for the selective degradation 
of ribosomes by autophagy [91]. In addition, it has recently been suggested that the ubiquitin 
ligase Rsp5 is specifically involved in the regulation of ribophagy [92]. Based on these 
observations, it has been postulated that ubiquitination of ribosomal subunits or associated 
factors by Rsp5 may provide a specific engulfment signal, and a subsequent 
Ubp3/Bre5-dependent de-ubiquitination step may allow the maturation and/or fusion of the 
autophagosome with the vacuole. The human homologues of Ubp3 and Bre5, USP10 and its 
modulator G3BP1, have been identified, but have no currently known function. Recently, a 
critical regulator of autophagy, namely the Atg1p homologue Ulk1, has been implicated in the 
autophagic clearance of ribosomes during reticulocyte maturation [93]. 
 
Xenophagy – The selectivity of autophagy is not restricted to cellular components but is also 
applicable to pathogens. Xenophagy, a process that has only been characterized in higher 
eukaryotes, denotes the specific elimination of intracellular microbes (e.g. group A 
Streptococcus) through an autophagy-related process. Interestingly, several pathogens 
manipulate the autophagic process in their mammalian host cells in order to survive and to 
establish a persistent infection. The bacterium Shigella flexneri for example, produces a 
protein by which it escapes recognition for autophagic sequestration [94]. 
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Figure 1.3. Selective and non-selective types of autophagy in yeasts and higher eukaryotes 
See text for more details. Figure adapted and modified from Klionsky et al., 2007 [95]. 
 
 
3.2.2. Organellar types of selective autophagy 
Mitophagy – The term mitophagy refers to the selective degradation of mitochondria by 
autophagy [96]. By eliminating aged and defective mitochondria, mitophagy serves a key role 
in maintaining mitochondrial functionality and protecting cells from the harm of disturbed 
mitochondrial metabolism and release of proapoptotic proteins. Interestingly, mitophagy is 
preferentially mediated by microautophagy in yeasts and macroautophagy in mammals. 
During the last few years, the specific signals that target individual mitochondria for 
autophagic degradation have begun to be elucidated. In yeasts, the outer mitochondrial 
membrane protein Uth1 and the mitochondrial protein phosphatase Aup1 are reported to be 
indispensable for mitophagy [97,98]. In addition, osmotic swelling and organelle 
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fragmentation caused by depletion of the mitochondrial inner membrane protein Mdm38, 
induces mitophagy. It has been suggested that fission of the swollen organelle triggers the 
autophagic machinery. This idea is corroborated by the finding that inhibition of the fission 
protein Dnm1 blocks mitophagy. Very recently, a new protein that is localized on 
mitochondria and named Atg32p, has been identified as a recognition factor for selective 
mitochondrial sequestration [99]. In mammals, loss of mitochondrial membrane potential and 
opening of the mitochondrial permeability transition pore seem to be common prerequisites 
for mitophagy. Irreversibly depolarized mitochondria caused by laser-induced photodamage 
in living hepatocytes, are rapidly and selectively degraded by autophagy [96]. As 
mitochondria dynamically undergo fission and fusion events, several studies in mammals 
have indicated a clear link between the mitochondrial fission/fusion machinery and 
mitophagy. Twig and collaborators proposed a quality control mechanism in the 
mitochondrion’s life cycle based on the observations they made by tracking several individual 
mitochondria through rounds of fission and fusion [100]. Fission yields daughter mitochondria 
with opposite deflections in mitochondrial membrane potential. The mitochondrion that 
maintains an intact membrane potential undergoes a subsequent fusion event and continues its 
life cycle, while the depolarized mitochondrion is targeted for autophagic degradation. This 
system allows the segregation and elimination of damaged mitochondrial components from 
the functional networking population. Recently, the ubiquitin ligase Parkin has been shown to 
be recruited from the cytoplasm to depolarized and consequently fragmented mitochondria 
and to mediate their autophagic degradation [101]. Accordingly, a deficiency in the fusion 
protein Opa1 or in the fission protein Drp1 has been shown to correlate with increased or 
reduced mitophagy, respectively [102]. Two other proteins that are essential for the selective 
autophagic clearance of mitochondria in mammalian cells, namely the Atg1p homologue 
Ulk1 and the Bcl-2 family member Nix, were identified by using an erythroid maturation 
model [93,103]. Like peroxisomes, mitochondria are also linked to cellular ageing. The 
age-related diminishment of autophagic activity has been postulated to be a critical factor in 
accelerating the mitochondrial mechanisms of ageing such as accumulation of ROS and 
mtDNA mutations and release of proapoptotic proteins. The link between mitophagy and 
ageing has also been reported in yeasts, where deletion of Uth1 blocks mitophagy and 
decreases longevity during nutrient deprivation [96]. 
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ER-phagy – Also the ER appears to be a selective target for autophagic degradation. Early 
studies on the reversal of phenobarbital-induced proliferation of smooth ER in rat liver 
showed a selective sequestration of smooth ER membranes by autophagic vacuoles upon 
withdrawal of the drug [104]. A similar phenomenon was recently observed in yeasts, under 
conditions of ER stress. The protein folding capacity of the ER is regulated at multiple 
levels [105]. ER-associated degradation (ERAD) mediates the retrotranslocation of unfolded 
proteins from the ER lumen into the cytosol for degradation by the proteasome. When the 
protein folding demand largely exceeds the protein folding capacity of the ER, the overload of 
misfolded proteins is sensed by an ER-to-nucleus signaling pathway, called the unfolded 
protein response (UPR). Induction of the UPR leads to the transcriptional activation of ERAD 
components and ER chaperones and to a massive expansion of the ER volume. Upon UPR 
inactivation, superfluous ER is removed by autophagy, a process that is termed ER-phagy or 
reticulophagy [106]. The physiological role of ER-phagy may be two-fold: (i) reducing ER 
size after the folding stress induced enlargement and (ii) sequestering damaged parts of the 
ER containing potentially toxic aberrant proteins. Surprisingly, the selective sequestration by 
autophagosomes rather than the degradation of portions of the ER is sufficient to alleviate ER 
stress. In addition, several studies in mammalian systems indicate that ER stress triggers 
autophagy [105]. The theory of autophagy as an ER detoxification mechanism is for instance 
supported by the finding that the autophagic pathway is involved in ridding the ER of toxic 
protein aggregates in liver cells derived from patients suffering from ER storage diseases (e.g. 
α1-antitrypsin defiency) [107]. Taken together, quite a few observations in yeast and 
mammalian systems indicate an important role for autophagy in the protection against cell 
death induced ER stress. However, the general mechanisms of ER-phagy – how ER fragments 
are generated and selectively removed by autophagy – remain largely unknown. 
 
Piecemeal microautophagy of the nucleus – During piecemeal microautophagy of the 
nucleus (PMN), nonessential parts of the S. cerevisiae yeast nucleus – the most vital material 
for cell survival, i.e. chromatin, is neatly excluded – are targeted for degradation in the 
vacuole. PMN occurs in the context of nuclear vacuolar (NV) junctions4
                                               
4 NV junctions are Velcro-like patches formed by interactions between the vacuolar membrane protein Vac8 and 
its nuclear counterpart Nvj1. They represent the first well-defined interorganellar connections [108]. 
 where portions of the 
LITERATURE OVERVIEW 
29 
 
nuclear envelope and associated nucleoplasmic components are sequestered into an 
invagination of the vacuole membrane, forming a nuclear bleb. Eventually, the bleb is 
pinched off from the nucleus, released into the vacuole lumen, and degraded by vacuolar 
hydrolases [108]. The selectivity of PMN is determined by interactions between Vac8 in the 
vacuole membrane and Nvj1 in the nuclear envelope. Two additional proteins, Osh1 and 
Tsc13, both involved in the biosynthesis and trafficking of lipids, seem to contribute to the 
biogenesis of PMN structures. Presumably they facilitate the extensive membrane bending, 
scission, and fusion events that take place during the PMN process. In response to nutrient 
depletion, PMN is induced through the expansion of NV junctions and the increased binding 
of Osh1 and Tsc13 by Nvj1 [108]. Importantly, PMN is currently the only microautophagic 
pathway for which the molecular basis of cargo recognition is known. So far, no analogous 
mechanism and no homologous genes have been identified in mammalian cells. Very 
recently, PMN has been characterized as a bona fide autophagic process as it requires a subset 
of ATG genes constituting the core autophagic machinery [109]. 
 
Lipophagy – The most recently identified organellar type of selective autophagy is called 
lipophagy [110]. This process promotes the lysosomal degradation of lipid droplets (LD), i.e. 
neutral lipid storage organelles that serve as major energy reservoirs in all organisms. Under 
basal conditions lipophagy may act as a homeostatic regulator that controls the size and 
number of LDs, whereas the considerable increase of LD-containing autophagosomes under 
stress conditions highlights the physiological significance of lipophagy for cell survival. 
 
Pexophagy – The selective degradation of peroxisomes by autophagy is termed pexophagy 
and is described in more detail in the following sections. 
 
3.3. PEROXISOME DEGRADATION IN YEASTS 
3.3.1. Macropexophagy versus micropexophagy 
The selective removal of peroxisomes by autophagy was first described in yeasts. During the 
last decade, yeast studies have significantly contributed to the unraveling of the structural and 
molecular characteristics of pexophagy. Especially the methylotrophic yeast species 
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H. polymorpha and P. pastoris turned out to be very suitable model organisms for this 
purpose as they rapidly adapt peroxisome size and number upon changing the carbon source 
in their growth medium (see 1.3. p.7). At least two basic modes of selective peroxisome 
degradation have been described, namely macro- and micropexophagy, analogous to macro- 
and microautophagy [111]. A switch from methanol to glucose induces macropexophagy in 
H. polymorpha and micropexophagy in P. pastoris, whereas ethanol adaptation promotes 
macropexophagy in both yeast species. Moreover, in P. pastoris, the mode of pexophagy does 
not only depend on the carbon source but also on the intracellular ATP levels [112]. 
 
During macropexophagy, individual peroxisomes are sequentially and selectively sequestered 
by a pexophagosome which subsequently fuses with the vacuolar membrane (Figure 1.4.B 
p.32). In micropexophagy, which has been extensively studied in P. pastoris, the vacuolar 
membrane itself forms protrusions around a cluster of peroxisomes (Figure 1.4.A p.32). The 
sealing of the vacuole is assisted by a cup-shaped double membrane structure, called the 
micropexophagy-specific membrane apparatus (MIPA), which is synthesized at the 
peroxisomal surface [113]. The MIPA is believed to heterotypically fuse with both vacuolar 
arms, mediating the incorporation of the peroxisome cluster into the lumen of the vacuole. 
Both MIPA and pexophagosome formation require the complete set of core Atg proteins 
together with some additional pexophagy-specific factors. Very recently, Atg30p has been 
identified as the peroxisome receptor for both macro- and micropexophagy in 
P. pastoris [114]. During peroxisome proliferation, Atg30p localizes at the peroxisome 
surface by interacting with the peroxisomal membrane proteins Pex3p and Pex14p. Upon 
induction of pexophagy, Atg30p is phosphorylated and delivers peroxisomes to the PAS – the 
site where the MIPA or the pexophagosome will form – through binding to Atg11p and 
Atg17p [114]. Unlike Atg11p, which is involved in the Cvt pathway, Atg30p is not needed for 
other selective or non-selective autophagy-related processes. Other pexophagy-specific 
components required for pexophagosome formation include Atg25p in H. polymorpha and the 
UDP-glucose:sterol glucosyltransferase Atg26p in P. pastoris. In the final step of pexophagy, 
Atg24p, Vam7, and Vac8, are involved in the fusion of the MIPA or pexophagosome with the 
vacuolar membrane [115]. 
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Very recently, the size of peroxisomes has been correlated to peroxisome turnover: the larger 
the peroxisome, the more different pexophagy-specific Atg proteins are required for its 
degradation [116]. Remarkably, also peroxisome number seems to play a role as 
H. polymorpha mutants containing one single peroxisome are not susceptible for 
pexophagy [19]. Another interesting finding concerns the role of autophagic peroxisome 
degradation in cellular housekeeping in H. polymorpha. During chemostat cultivation of 
wild-type cells, entire peroxisomes were observed to be constitutively degraded by autophagy 
during normal vegetative growth. Since the half-life of peroxisomal proteins is not affected by 
the absence of peroxisomal Lon protease, these data imply that the autophagic degradation of 
peroxisomes might be the major mechanism of peroxisomal housekeeping in yeasts [117]. 
 
3.3.2. Role of Pex3p and Pex14p 
In the methylotrophic yeast H. polymorpha, the peroxisomal membrane proteins Pex3p and 
Pex14p – both key components of peroxisome biogenesis – have been shown to be involved 
in the initial recognition of peroxisomes by the autophagic machinery. At the onset of 
macropexophagy, Pex3p is rapidly removed from the peroxisomal membrane and degraded 
by the proteasome [118]. Unlike Pex3p, Pex14p needs to be present at the peroxisomal 
membrane suggesting that peroxisome sequestration initiates at the site of Pex3p removal and 
Pex14p recognition [119]. Further analysis demonstrated that the highly conserved N-terminal 
region of Pex14p is required for macropexophagy and probably serves as the recognition 
factor for the putative receptor protein [119]. Moreover, very low amounts of Pex14p seem to 
be sufficient for recognition [120]. The current model regarding the mechanism of Pex3p- and 
Pex14p-dependent pexophagy is based on the finding that Pex3p connects the docking and 
translocation subcomplexes during peroxisomal matrix protein import [121]. It has been 
hypothesized that upon removal of Pex3p, the import complexes dissociate, further import of 
matrix proteins is blocked, and the N-terminus of Pex14p is exposed and recognized for 
sequestration of the peroxisome by the pexophagosome [111]. The fact that Pex14p is not 
needed for N-starvation induced general microautophagy in H. polymorpha suggests that its 
role is limited to selective peroxisome degradation [120]. 
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Figure 1.4. Peroxisome degradation pathways 
(A) During micropexophagy, a cluster of peroxisomes (P) is directly engulfed by vacuolar/lysosomal (V/L) 
protrusions. Before complete sequestration, a novel membrane structure, called MIPA (black) – a structure only 
described in yeasts – is formed and mediates fusion between the tips of the invaginating vacuole. 
(B) Macropexophagy involves the sequestration of a single peroxisome (P) by an isolation membrane resulting 
in the formation of a pexophagosome (Px). Upon fusion of the outer membrane of the pexophagosome with the 
vacuolar/lysosomal membrane, the residual pexophagic body (Pb) enters the vacuole/lysosome (V/L) and is 
degraded by vacuolar/lysosomal hydrolases. (C) During 15-lipoxygenase-mediated autolysis, the peroxisomal 
membrane is disrupted by 15-lipoxygenase (15-LOX) which leads to diffusion of the peroxisomal content into 
the cytosol and degradation of the content by the cytosolic proteolytic system. 15-LOX-mediated autolysis has 
only been described in mammalian cells whereas the micro- and macroautophagic degradation of peroxisomes 
has been observed in both mammalian and yeast cells. 
 
 
3.4. PEROXISOME DEGRADATION IN MAMMALS 
3.4.1. Macroautophagy 
Early evidence for the selective autophagic degradation of peroxisomes in mammals was 
provided by morphological studies of liver cells derived from rats that were treated with the 
peroxisome proliferator DEHP. In the first week after withdrawal of DEHP, the number of 
proliferated peroxisomes decreased drastically. Blocking lysosomal processing by the 
protease inhibitor leupeptin induced the accumulation of autophagosomes containing large 
proliferated peroxisomes, indicating the selectivity of this process [122]. More recently, the 
analysis of ATG7-deficient mouse livers has shown that the selective clearance of superfluous 
peroxisomes is mainly – if not entirely – dependent on macroautophagy [123]. This made the 
core autophagy protein Atg7p the first factor involved in the process of peroxisome 
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degradation in mammalian cells. Meanwhile, some additional components have been 
identified. Based on studies in Chinese hamster ovary (CHO) cells, Fujiki and coworkers 
reported that upon starvation and reculture, peroxisomal proteins are preferentially degraded 
by autophagy in comparison to cytosolic proteins. Furthermore, they suggested that Pex14p 
contributes to this process by interacting with membrane-bound LC3-II under starved 
conditions [124]. The physiological significance of these observations remains to be defined. 
Finally, Atg12p – which also belongs to the core autophagy machinery – has recently been 
shown to play a role in the autophagic degradation of peroxisomes in mammals [125]. 
 
How are damaged, superfluous, or non-functional peroxisomes in mammalian cells 
recognized for sequestration and subsequent degradation? A plausible answer to this 
intriguing question may be ubiquitination. Recent data have demonstrated that ubiquitin 
serves as a signal to specifically target peroxisomes for autophagic degradation through a 
p62-dependent pathway [125]. The p62 protein, also known as sequestosome 1 (SQSTM1), is 
an adaptor protein that has been implicated in a variety of signal cascades [126]. In addition, 
p62 has the ability to bind ubiquitin non-covalently through its C-terminal 
ubiquitin-associated domain. Interestingly, Pankiv et al. recently showed a direct interaction 
between p62 and LC3, mediating the autophagic degradation of p62-positive inclusion bodies 
containing polyubiquitinated protein aggregates [127]. The idea that p62 may act as an 
autophagic receptor for ubiquitinated cargo has been further supported by the observation that 
peroxisomes expressing a PMP34-ubiquitin fusion protein are targeted for autophagic 
degradation through a pathway involving p62 [125]. Moreover, p62 is required for normal 
peroxisome turnover implying that regulation of basal peroxisome levels may involve 
ubiquitination of a peroxisomal membrane protein [125]. Which endogenous PMPs are 
ubiquitinated to activate pexophagy remains enigmatic and will be an important focus of 
further research. Very recently, NBR1 (neighbor of BRCA1 gene 1), having a similar domain 
architecture as p62, was identified as an additional LC3- and ubiquitin-binding protein [126]. 
It has been suggested that both p62 and NBR1 cooperate in the recognition and clearance of 
ubiquitinated targets by autophagy [126]. 
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3.4.2. Microautophagy 
In 2005, it has been suggested that peroxisome degradation in CHO cells is dependent on 
microautophagy [128]. In this study, a tetracycline-controlled gene expression system was 
used to investigate recombinant rat urate oxidase (UOX), which is not endogenously 
expressed in CHO cells. In the absence of tetracycline, functional recombinant UOX protein 
was present in crystalloid structures within peroxisomes. Upon addition of tetracycline, the 
UOX mRNA was rapidly broken down while the UOX protein reduced gradually and was 
completely eliminated only after 10 days. Based on electron microscopic analyses, the authors 
suggest that entire peroxisomes rather than the single recombinant rat UOX protein within 
these organelles are degraded and that the microautophagic pathway may play a major role in 
this process. It is important to note that these conclusions are based on an artificial situation 
for which it has to be taken into consideration that exogenous recombinant crystallized 
proteins may trigger other degradation pathways than the ones occurring under physiological 
conditions. Until now, there is no further evidence for degradation of peroxisomes by 
microautophagy in mammalian cells. 
 
3.4.3. 15-Lipoxygenase-mediated autolysis 
In addition to the classical pathways, a non-autophagic pathway, called 15-lipoxygenase-
mediated autolysis, has been proposed as a possible alternative mechanism for peroxisome 
degradation in mammals. During the differentiation of specific cell types such as reticulocytes 
and lens fiber cells, 15-lipoxygenase (15-LOX) activity is responsible for ridding the cell of 
organelles. By integrating into organellar membranes, 15-LOX causes focal membrane 
disruptions which lead to the release of the organelles’ content into the cytosol and the 
digestion of the content by cytosolic proteases (Figure 1.4.C p.32) [24]. In addition, 15-LOX 
was detected on the membranes of some but not all peroxisomes in aldehyde-fixed sections of 
normal rat liver. Prolonged incubation of the slices in a buffer preserving 15-LOX activity 
induced peroxisomal membrane disruptions and diffusion of catalase out of the peroxisomes. 
Furthermore, these processes were significantly reduced in the presence of 15-LOX inhibitors. 
Based on these data, it has been postulated that 15-LOX may have a physiological role in the 
turnover of peroxisomes in rat hepatocytes [129]. 
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Although significant progress has been made in the elucidation of the molecular mechanisms 
underlying peroxisome biogenesis, the degradation process and turnover dynamics of these 
organelles in mammalian cells remain only poorly characterized. The main reason for this is 
the lack of a reliable model system. Indeed, at the start of this work, studies in mammals were 
limited to the morphological description of the degradation of proliferated peroxisomes after 
withdrawal of the proliferation stimulus. However, this approach suffers two important 
drawbacks: (i) the decrease in peroxisome number during recovery from the proliferation 
stimulus is only two- to fivefold, and (ii) peroxisomes are still continually formed. Hence, the 
development of a suitable cell model to study peroxisome degradation at the molecular level 
under physiological conditions is a prerequisite to further unravel the mysterious aspects of 
the peroxisomal life cycle. 
 
Development of a cell model to study peroxisome dynamics 
Our aim was to develop a reliable mammalian cell model that can be used to characterize 
peroxisome degradation under basal conditions and to identify proteins that are involved in 
this process. For this purpose, we made use of two different approaches. In the first approach, 
we endeavored to generate a cell line in which peroxisome abundance can be controlled in a 
tunable manner allowing us to study the degradation process of pre-existing peroxisomes. 
Note that such a model system would also provide us with an interesting tool to investigate 
the initial stages of peroxisome biogenesis. The second approach was based on the 
development of a cell model in which peroxisomes can be visualized by using an in vivo 
pulse-labeling technique. The results of this work, which mainly focus on peroxisome 
dynamics, constitute the major part of this thesis and are discussed in Chapters III, IV, and V. 
 
The Zellweger syndrome: a case study 
During the course of this project, a patient suffering from Zellweger syndrome was clinically 
characterized in the University Hospital of Leuven. In terms of collaboration, we analyzed 
some biochemical parameters related to peroxisomal lipid metabolism and we performed 
complementation studies and mutation analysis on the patient’s fibroblasts in order to unravel 
the underlying molecular defect. The results of this case study are discussed in Chapter VI. 
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1. INTRODUCTION 
Because of their role in a wide spectrum of metabolic activities (see Chapter I section 1.1.), 
peroxisomes are indispensable organelles for human development [1]. Therefore, maintaining 
a healthy peroxisome population is of great importance. Peroxisome abundance is tightly 
controlled by three major pathways [2]. First, pre-existing peroxisomes can undergo fission 
events, a process referred to as peroxisome multiplication [3]. Next, exposure of a cell to 
various environmental stimuli triggers peroxisome proliferation which results in a significant 
increase in the number of peroxisomes within a short period of time [3]. Finally, the number 
of peroxisomes is regulated by peroxisome turnover which mainly involves autophagic 
degradation of the organelles [4]. During the past decades, considerable progress has been 
made in the elucidation of the molecular mechanisms underlying peroxisome biogenesis. 
More recently, there is a growing interest in how peroxisomes are degraded. Interestingly, the 
autophagic degradation of peroxisomes, also called pexophagy, most likely prevents the 
accumulation of non-functional and superfluous peroxisomes and seems to play an important 
role in both the quality control of the organelle and cellular housekeeping [5]. Methylotrophic 
yeast species have proven to be suitable organisms to study pexophagy and have already 
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yielded a lot of insight into the molecular machinery involved in this process. However, due 
to the lack of an apposite study model in mammals, the molecular mechanisms of peroxisome 
degradation in mammalian species are relatively poorly understood. This prompted us to 
generate a mammalian cell system in which peroxisome membrane biogenesis can be 
switched on and off in a controllable manner. Since the peroxins Pex3p, Pex16p and Pex19p 
are essential for the formation of the peroxisomal membrane, they may serve as potential 
target candidates. However, as – at the start of this project – it was known that various 
fragments of the peroxisomal membrane protein Pex3p render a dominant-negative 
phenotype [6], we intended to use a dominant-negative variant of this peroxin in combination 
with the Flp-In T-REx system (Invitrogen) to generate our mammalian cell model. The 
availability of such a model, which would allow us to control peroxisome biogenesis by 
varying the concentration of tetracycline, would greatly facilitate our research regarding the 
molecular mechanisms of peroxisome degradation in mammalian cells. In addition, such a 
model would be a suitable tool to study the initial stages of peroxisome biogenesis. 
 
 
2. MATERIALS AND METHODS 
2.1. Materials 
Blasticidin S HCl, Zeocin, and hygromycin B were all purchased from Invitrogen. 
Tetracycline HCl and doxycycline hyclate were from Sigma-Aldrich. The vector for transient 
expression of Flp recombinase, pOG44, was obtained from Invitrogen. 
 
2.2. Plasmids 
The Flp-In T-REx expression vector pcDNA5/FRT/TO and restriction enzymes were 
purchased from Invitrogen and TaKaRa, respectively. The oligonucleotides used in this study 
were synthesized by Eurogentec. Polymerase chain reactions were routinely performed using 
Pfx DNA polymerase (Invitrogen). Constructs were made by using standard molecular 
cloning techniques. Plasmids pTW104 (encoding HsPex3p(1-44)-EGFP), pTW105 (encoding 
HsPex3p(1-373)-EGFP), pTW123 (encoding HsPex3p(1-106)-EGFP), pTW124 (encoding 
HsPex3p(1-143)-EGFP) and pMF158 (encoding Gal4pBD-HsPex3p(1-373)) have been described 
elsewhere [7]. Plasmid pSH8, a derivative of the pcDNA5/FRT/TO vector containing the 
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coding sequence for HsPex3p(1-44), was constructed by cloning the Kpn I/Xho I-digested PCR 
product [template: pMF158; primers: HsPex3FW.KpnI (5’-CGGGGTACCGTAATGGTG 
AGGTCTGTATGG-3’) and HsPex3.44RV.BamHI.XhoI (5’-CGGCTCGAGCTACTGAC 
GGATCCTCTCCCTTTCCTGTATTTC-3’)] into the Kpn I/Xho I-restricted vector. 
Subsequently, plasmid pSH10 (encoding HsPex3p(1-44)-3xmyc) was generated by ligating 
Bam HI/Xho I-digested pSH8 to a DNA linker obtained by annealing the oligonucleotides 
3xmyc,fw (5’-GATCATGGGACAGAAGCTGATCTCAGAGGAGGACCTGGAGCAGAA 
ACTCATCTCTGAAGAAGATCTGGAACAAAAGTTGATTTCAGAAGAAGATCTG-3’) 
and 3xmyc,rv (5’-TCGACAGATCTTCTTCTGAAATCAACTTTTGTTCCAGATCTTCTT 
CAGAGATGAGTTTCTGCTCCAGGTCCTCCTCTGAGATCAGCTTCTGTCCCAT-3’) 
(encoding three copies of the c-myc epitope). All constructs were verified by DNA sequence 
analysis (Agowa). 
 
2.3. Antibodies 
The mouse polyclonal antiserum against bovine catalase [8] and the rabbit polyclonal 
antiserum against HsPex14p [9] have been described elsewhere. The 1-9E10.2 hybridoma cell 
line producing anti-myc antibody [10] was obtained from A.T.C.C. Alexa Fluor 488-
conjugated anti-mouse and Texas Red-conjugated anti-rabbit antibodies were from Invitrogen 
and Merck, respectively. 
 
2.4. Cell culture 
All cell lines were cultivated under standard conditions (37°C, 5% CO2). CHO cells were 
maintained in minimal essential medium Eagle alpha (MEMα) (Lonza). C33a Flp-In T-REx 
cells5 (kindly provided by Dr. S. Müller, Max Planck Institute, Martinsried, Germany) [11] 
and 293 Flp-In T-REx cells6
                                               
5 C33a is a human papillomavirus (HPV)-negative cervical carcinoma cell line. 
 (kindly provided by Dr. F. Claessens, K.U.Leuven, Belgium) 
were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Lonza) supplemented with 
150 µg/ml or 100 µg/ml Zeocin and 75 µg/ml or 15 µg/ml blasticidin, respectively. 
Transfection experiments were performed using Lipofectamine Plus (Invitrogen). To generate 
stable cell lines, Flp-In T-REx cells were transfected with the pSH10 plasmid. Three days 
6 293 denotes a human embryonic kidney (HEK) 293 cell line. 
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later, cells with a Flp-mediated integration of the plasmid were selected with 200 µg/ml (C33a 
cells) or 100 µg/ml (HEK293 cells) hygromycin in the presence of blasticidin (but in the 
absence of Zeocin). 
 
2.5. Immunofluorescence microscopy 
Cells were fixed with 4% (w/v) paraformaldehyde for 20 min and permeabilized in 1% (w/v) 
Triton X-100 for 5 min. After permeabilization, the nuclei were stained by incubating the 
cells for 45 s with 4’,6-diamidino-2-phenylindole (DAPI) (0.5 µg/ml). Non-specific antigen 
sites were blocked with 5% (w/v) bovine serum albumin for 15 min. After each step, the cells 
were washed three times with phosphate-buffered saline (PBS). Next, the cells were incubated 
with primary antibody for 1 h, followed by a 1 h incubation with a fluorophore-labeled 
secondary antibody conjugate. After each incubation step, the cells were extensively washed 
with PBS. Finally, the coverslips were mounted on glass slides using Mowiol 4-88 mounting 
medium. All procedures were performed at room temperature. Mitochondria were visualized 
by incubating the cells for 45 min with 2 µM MitoTracker Red (Molecular Probes Invitrogen) 
prior to fixation. Samples were analyzed on an Olympus IX81 inverted fluorescence 
microscope with 60X-oil and 100X-oil immersion objectives. Fluorescence was monitored 
with a CellM imaging station (Olympus) equipped with U-MNUA2, U-MNIBA3 and 
U-MWIY2 fluorescence mirror units. 
 
2.6. β-galactosidase assay 
To measure β-galactosidase activity, cell lysates [prepared by sonication in PBS containing a 
mixture of protease inhibitors (1 µg/ml aprotinin, 0.5 µg/ml leupeptin, 1 µg/ml 
α2-macroglobulin, and 1 µg/ml chymostatin) (Sigma)] were diluted and incubated in reaction 
buffer (200 mM Hepes pH 8.0, 10 mM dithiothreitol, 0.1% (w/v) Triton X-100, 1 mM MgCl2) 
in the presence of the β-galactosidase substrate chlorophenol red β-D-galactoside (final 
concentration 2 mM; Boehringer Mannheim). The reaction was followed at 575 nm for 
20 min at 30°C [Van Veldhoven PP, unpublished data]. Protein content was determined by 
using the modified Lowry method [12] and specific β-galactosidase activity was calculated. 
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3. RESULTS 
3.1. Verification of the dominant-negative phenotype of Pex3p variants 
The dominant-negative phenotype of a number of Pex3p variants has been reported by 
Soukupova and colleagues who observed that expression of shorter forms of HsPex3p often 
resulted in the disappearance of peroxisomes and the mislocalization of these proteins to 
mitochondria [6]. At the start of this work, HsPex3p(1-44), HsPex3p(1-106), HsPex3p(1-143), and 
full-length HsPex3p, were transiently expressed in CHO cells as C-tagged EGFP fusion 
proteins. One to three days after transfection, their effect on peroxisome biogenesis was 
analyzed by immunofluorescence microscopy using antibodies against catalase, a peroxisomal 
matrix protein, and Pex14p, a peroxisomal membrane protein. Peroxisome biogenesis was 
drastically disturbed in cells overexpressing HsPex3p(1-44)-EGFP (Figure 3.1.). That is, after 
two days, peroxisomes were virtually absent in more than 50% of the transfected cells. 
Interestingly, HsPex3p(1-44)-EGFP itself displayed a mitochondrial localization pattern in these 
cells which is in line with previous findings [6]. Note that, upon overexpression of 
HsPex3p(1-44)-EGFP, mitochondria often clustered (Figure 3.1.), a phenomenon that has also 
been observed upon co-overexpression of Pex11p and Fis1 [13]. Since low expression levels 
(as judged from the fluorescence intensity) resulted in a peroxisomal localization (data not 
shown), we assume that the subcellular localization of the Pex3p variant depends on its 
expression levels. This phenomenon has also been described for other peroxisomal membrane 
proteins (e.g. PMP52) [14]. As no peroxisomal and mitochondrial abnormalities were 
observed upon overexpression of EGFP alone (Figure 3.1.), HsPex3p(1-44) was used to 
generate our cell model. 
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Figure 3.1. Overexpression of HsPex3p(1-44) has a dominant-negative effect on peroxisome abundance 
CHO cells were transiently transfected with a plasmid encoding EGFP (two upper rows) or HsPex3p(1-44)-EGFP 
(lower rows). 24 hours posttransfection, mitochondria were stained with MitoTracker Red (row 1 and 3) and 
cells were fixed and processed for (immuno)fluorescence microscopy. Antibodies against catalase (row 2 and 4) 
and Pex14p (row 5) were used. Representative images are shown. Scale bars represent 10 µm. 
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3.2. Generation of a HsPex3p(1-44) Flp-In T-REx cell line 
The Flp-In T-REx system (Invitrogen) was used to generate a stable cell line in which the 
expression of HsPex3p(1-44) can be induced with tetracycline or its analogue doxycycline 
(Figure 3.2.). To detect HsPex3p(1-44), we expressed the protein with a C-terminal 
3xmyc-sequence (this sequence was chosen to avoid interference of EGFP fluorescence with 
microscopic analyses). Initially, we confirmed the dominant-negative phenotype of 
HsPex3p(1-44)-3xmyc by transiently expressing this protein in CHO cells (Figure 3.3., upper 
panels). For the production of stable cell lines, the Flp-In T-REx host cell line (containing a 
single integrated Flp recombination target (FRT) site and stably expressing a Tet repressor) 
was cotransfected with pSH10 and pOG44. pSH10 is a pcDNA5/FRT/TO derivative which 
encodes HsPex3p(1-44)-3xmyc (under control of a tetracycline-regulated promoter) and 
contains a FRT site linked to the hygromycin resistance gene. pOG44 is a plasmid encoding 
the Flp recombinase. Upon cotransfection, the Flp recombinase mediates a homologous 
recombination between the FRT sites in the host cells and the pcDNA5/FRT/TO expression 
vector resulting in the integration of the expression vector at a specific site in the host cell 
genome. In the mock conditions, pOG44 was not included. Three days after transfection, 
selection medium containing hygromycin was added to the cells and approximately three 
weeks later hygromycin-resistant foci could be visually identified and isolated. After 
expanding the cells, the clones were tested for Zeocin sensitivity and lack of β-galactosidase 
activity to verify inactivation of the Zeocin-LacZ fusion gene which implies the integration of 
the pcDNA5/FRT/TO construct into the FRT site. Finally, inducible expression was tested by 
incubating the cells in the absence and presence of doxycycline and analyzing them by 
immunofluorescence microscopy and Western blotting. 
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Figure 3.2. Principle of the Flp-In T-REx system 
Figure adapted from the Flp-In T-REx system manual (Invitrogen). 
 
 
Both C33a and 293 Flp-In T-REx cells were used. In case of the C33a Flp-In T-REx cell line, 
the tested clones showed some residual β-galactosidase activity. In addition, none of the cell 
populations displayed a uniform expression pattern (Figure 3.3., lower panels). Nevertheless, 
the tetracycline-regulated expression of the system could be confirmed by the fact that 
HsPex3p(1-44) was expressed in cells cultivated in the presence of doxycycline, but not in 
non-treated cells (data not shown). For the 293 Flp-In T-REx cell line, approximately 40% of 
the clones (19 clones tested) were sensitive to Zeocin and completely lacked β-galactosidase 
activity indicating a correct integration of the expression vector into the genome of the host 
cell line. However, immunofluorescence studies and Western blot analysis showed that the 
expression levels of HsPex3p(1-44) obtained after induction were too low to result in a 
dominant-negative phenotype. Attempts to increase the expression levels by varying the 
concentration of doxycycline (10 ng/ml – 4000 ng/ml) were not successful (data not shown). 
 
 
HsPex3p(1-44)-3xmyc
genome Flp-In T-REx host cell line
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Figure 3.3. Expression of HsPex3p(1-44) in CHO cells and C33a Flp-In T-REx cells 
The upper panels represent CHO cells transiently expressing HsPex3p(1-44)-3xmyc which were fixed 40 hours 
posttranfection. The lower panels show a C33a Flp-In T-REx cell line which was selected for stable genomic 
integration of the pcDNA5/FRT/TO derivative encoding HsPex3p(1-44)-3xmyc and grown in the presence of 
doxycycline (1 µg/ml) for 48 hours. HsPex3p(1-44)-3xmyc and the peroxisomal marker protein Pex14p were 
visualized by immunostaining. Scale bars represent 10 µm. 
 
 
4. DISCUSSION 
In this study, we could confirm the previous finding of Soukupova and collaborators [6] that 
HsPex3p(1-44), an N-terminal fragment of Pex3p encompassing the mPTS, can exert a 
dominant-negative effect on peroxisome abundance. However, no such phenotype could be 
observed upon treatment of Flp-In T-REx cell lines for HsPex3p(1-44) with doxycycline. Since 
(i) our initial transient expression experiments indicated that the dominant-negative effect of 
HsPex3p(1-44) correlates with its expression levels, and (ii) doxycycline-induced expression of 
this protein can not be detected on Western blot (data not shown), we believe that – under the 
conditions employed – the expression levels of HsPex3p(1-44) are not sufficiently high to result 
in a drastic decrease in peroxisome number. In conclusion, our results show that a Flp-In 
T-REx cell line with tetracycline-controlled expression of HsPex3p(1-44) is no suitable tool to 
regulate peroxisome abundance in mammalian cells. 
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1. ABSTRACT 
Despite the identification and characterization of various proteins that are essential for 
peroxisome biogenesis, the origin and the turnover of peroxisomes are still unresolved critical 
issues. In this study, we employed the HaloTag technology as a new approach to examine 
peroxisome dynamics in cultured mammalian cells. This technology is based on the formation 
of a covalent bond between the HaloTag protein – a mutated bacterial dehalogenase which is 
fused to the protein of interest – and a synthetic haloalkane ligand which contains a 
fluorophore or affinity tag. By using cell-permeable ligands of distinct fluorescence, it is 
possible to image different pools of newly synthesized proteins, generated from a single 
genetic HaloTag-containing construct, at different wavelengths. Here we show that 
peroxisomes display an age-related heterogeneity with respect to their capacity to incorporate 
newly synthesized proteins. We also demonstrate that these organelles do not exchange their 
protein content. In addition, we present evidence that the matrix protein content of 
pre-existing peroxisomes is not evenly distributed over new organelles. Finally, we show that 
peroxisomes in cultured mammalian cells, under basal growth conditions, have a half-life of 
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approximately two days and are mainly degraded by an autophagy-related mechanism. The 
implications of these findings are discussed. 
 
 
2. INTRODUCTION 
Peroxisomes are dynamic organelles which proliferate and are degraded in response to a 
variety of environmental stimuli [1]. In order to regulate peroxisome function and restrain 
damage during cellular ageing, new peroxisomes need to be formed and superfluous and 
non-functional peroxisomes have to be (selectively) removed. Studies in yeasts, plants, and 
mammals have shown that the formation and maintenance of peroxisomes in each type of 
these organisms is under the control of at least 16 PEX genes [2,3]. The number of genes 
identified in the process of peroxisome degradation varies greatly from organism to 
organism [4,5]. Although many of the genes involved in these processes are conserved from 
lower to higher eukaryotes [6], the origin of peroxisomes and how these organelles are 
targeted for turnover are – to a large extent – still controversial and unresolved issues. 
 
Currently, two different mechanisms have been suggested to account for the formation of 
peroxisomes: growth and division of pre-existing organelles [7,8], and de novo formation 
from the endoplasmic reticulum [9]. The relative contribution of each of these pathways to 
peroxisome biogenesis in wild-type cells remains enigmatic. For example, two independent 
research groups have convincingly shown that peroxisomes multiply by fission of pre-existing 
peroxisomes in wild-type yeasts, and that a de novo formation of peroxisomes only occurs in 
cells lacking these organelles [10,11]. Another elegant study has shown that in growing 
wild-type mammalian cells new peroxisomes primarily arise from the ER rather than by 
division of pre-existing peroxisomes [12]. At the moment, it is not clear whether these 
apparently conflicting observations represent species- or condition-specific characteristics. 
 
At present, three morphologically distinct modes of peroxisome degradation have been 
described: (i) macroautophagy (macropexophagy), a process by which the peroxisome is first 
sequestered by a double or multimembrane structure – the autophagosome – and subsequently 
delivered to the lysosome; (ii) microautophagy (micropexophagy), a process by which the 
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organelle is directly sequestered by the lysosomal membrane; and (iii) 15-lipoxygenase-
mediated autolysis, a process in which 15-lipoxygenase is thought to integrate into the 
peroxisome membrane causing focal membrane disruptions, thereby leading to the organelle’s 
content being exposed to and degraded by cytosolic proteases [4,6,13,14]. The molecular 
mechanisms behind peroxisome degradation have already been studied intensively in yeasts, 
but are only poorly characterized in mammalian cells [14]. Several years ago, it has been 
suggested that in CHO cells peroxisome degradation is dependent on microautophagy [15]. 
More recently, the analysis of autophagy-deficient mouse livers has shown that the (selective) 
clearance of peroxisomes in mammalian cells is mainly – if not entirely – dependent on 
macroautophagy [16]. So far, five proteins (Atg7p, Atg12p, LC3, p62, and Pex14p) have 
already been implicated in this process [16-18]. 
 
In this study, we employed the HaloTag system – comprised of a reporter protein that binds 
with high speed and selectivity to synthetic ligands consisting of a haloalkane-reactive linker 
and a functional group [19,20] – to gain more insight into the formation and turnover 
dynamics of peroxisomes in mammalian cells (for additional information, see Supplemental 
Figure p.76-77). The implications of the findings obtained with this labeling approach, which 
allowed us to optically distinguish and quantitatively compare different generations of 
peroxisomes in individual cells, are discussed. 
 
 
3. MATERIALS AND METHODS 
3.1. Plasmids 
Cloning vectors were obtained from Promega (pHT2, pFC14K) or Clontech (pEGFP-N1), and 
the oligonucleotides used in this study were synthesized by Eurogentec. PCR applications 
were performed routinely using Pfx DNA polymerase (Invitrogen). Restriction enzymes were 
purchased from TaKaRa. The Escherichia coli strain TOP10F’ (Invitrogen) was used for all 
DNA manipulations. The mammalian expression plasmids pLA95 (encoding EGFP-PTS1), 
pMF120 (encoding HsPex14p-EGFP), and pTW172 (encoding HsPex16p-EGFP) have been 
described elsewhere [21-23]. The plasmid encoding HaloTag-PTS1 (pMF1434) was 
constructed by amplifying the HaloTag cDNA fragment by PCR [template: pHT2; primers: 
CHAPTER IV 
56 
 
pHT2fw2 (5’-GGGGGTACCGGATCCGATGGGGTCCGAAATCGGTACAGGC-3’) and 
pHTrvKSKLNotI (5’-GAGAGCGGCCGCGATATCACAGCTTGCTCTTGCCGGCCAG 
CCCGGGGAG-3’)], and cloning the Bam HI/Not I-digested PCR product into the backbone 
fragment of Bam HI/Not I-restricted pHT2. The plasmid encoding HsPex16p-HaloTag 
(pMF1465) was generated by co-ligating the restriction enzyme-digested PCR amplified 
HaloTag [template: pHT2; primers: pHT2fw2 and pHT2rvNotI (5’-AGGGAAGCGGCCGC 
CTACTT-3’); digested with Bam HI and Not I] and HsPEX16 [template: pTW172; primers: 
HsPex16fwSalI (5’-GGGGTCGACAGGATGGAGAAGCTGCGGCTC-3’) and 
HsPex16rvBglII (5’-GGGAGATCTCCCCAACTGTAGAAGTAG-3’); digested with Sal I 
and Bgl II] cDNA fragments into the Sal I/Not I-digested backbone fragment of pEGFP-N1. 
The plasmid encoding HsPex3p(1-230)-HaloTag (pMF1518) was constructed by ligating the 
restriction enzyme-digested PCR amplified HaloTag [template: pFC14K; primers: pHT2fw3 
(5’-ACACGGATCCAGATCTACCATGGGGTCCGAAATCGGTAC-3’) and pHT2rvNotI; 
digested with Bam HI and Not I] and HsPEX3 [template: pMF158; primers: HsPex3fwXhoI 
(5’-GGGGCTCGAGAAGATGGGGAGGTCTGTATGGAATTTTC-3’) and HsPex3.6 
(5’-GAAGGTCGACCAGGTCCTGTTCAGTAG-3’); digested with Xho I and Bam HI] 
cDNA fragments into the Xho I/Not I-digested backbone fragment of pEGFP-N1. All 
plasmids were verified by DNA sequencing (Agowa). 
 
3.2. Antibodies 
The mouse polyclonal antiserum against bovine catalase [24] and the rabbit polyclonal 
antiserum against HsPex14p [25] have been described elsewhere. The rabbit anti-HaloTag 
IgGs (Promega), the goat anti-mouse IgGs coupled to alkaline phosphatase (Sigma), and the 
goat anti-rabbit IgGs coupled to alkaline phosphatase (Sigma), Texas Red (Calbiochem), 
Alexa Fluor 488 (Invitrogen), or Alexa Fluor 350 (Invitrogen) were commercially obtained. 
 
3.3. Cell culture, transfections, and cell fusion assays 
CHO cells [26] and Pex5-/- mouse fibroblasts [27] were cultured in MEMα and DMEM, 
respectively, as described. Cells were transfected with Lipofectamine Plus (Invitrogen). To 
enrich cells expressing HsPex14p-EGFP, pMF120-transfected cells were cultivated in the 
presence of 300 µg/ml G418 (Sigma) for at least four weeks. To fuse cells from different cell 
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populations, they were (i) co-seeded in a FluoroDish (World Precision Instruments), 
(ii) cultured overnight to allow them to adhere and to establish contacts with neighboring 
cells, (iii) washed with 1 ml pre-warmed MEMα, and (iv) incubated (37°C) with 1.5 ml 
50% (w/v) PEG-1500 (Roche Diagnostics) for 45 s. After removal of the PEG-1500 solution, 
the cells were rinsed four times with pre-warmed MEMα and cultured in complete culture 
medium. To inhibit protein synthesis, autophagy, or proteasome activity, the cells were 
cultivated in the presence of 100 µg/ml cycloheximide (Janssen Chimica), 10 mM 
3-methyladenine (3-MA; Sigma-Aldrich), or 5 µM proteasome inhibitor [MG132 
(Sigma-Aldrich) or epoxomicin (Calbiochem)], respectively. 
 
3.4. Labeling of HaloTag fusion proteins in living cells and (immuno)fluorescence 
microscopy  
Single or sequential labeling of live cells expressing HaloTag fusion proteins was done for a 
specified period of time with the cell-permeable HaloTag TMR (5 µM) or/and HaloTag 
R110Direct (0.1 µM) ligands. Between sequential labeling reactions, the cells were incubated 
with the HaloTag biotin (5 µM) ligand. After each labeling reaction, the cells were 
extensively washed with PBS and incubated in standard growth medium for at least 30 min. 
The cells were subjected to live cell imaging (in culture medium without phenol red) or fixed 
and processed for (immuno)fluorescence microscopy. Processing of the cell samples was 
carried out as described [28]. Fluorescence was evaluated on a CellM imaging station 
(Olympus) equipped with U-MNUA2, U-MNIBA3, and U-MWIY2 fluorescence mirror units. 
The Olympus image analysis and particle detection software was used for quantitative image 
analysis. 
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4. RESULTS 
4.1. In vivo labeling of peroxisomes with the HaloTag technology 
To test the utility of the HaloTag technology for addressing biological questions regarding 
peroxisome dynamics, we first investigated whether or not the HaloTag, a protein displaying 
a cytoplasmic distribution pattern in mammalian cells (Figure 4.1.A, upper panels), could be 
properly targeted to peroxisomes after the addition of a C-terminal peroxisomal matrix protein 
targeting signal (PTS1). Therefore, we transiently expressed the HaloTag-PTS1 protein in 
different cell types, and visualized this reporter protein by cultivating the cells in the presence 
of a cell-permeable fluorescent HaloTag ligand. These experiments revealed that the 
HaloTag-PTS1 signals displayed a predominant peroxisomal staining pattern in wild-type 
cells (Figure 4.1.B), and a diffuse cytoplasmic staining pattern in cells in which peroxisomal 
matrix protein import is impaired (Figure 4.1.A, lower panels). Note that the weak but 
significant background labeling observed in the wild-type cells may arise from non-specific 
adsorption of residual ligand and/or labeled HaloTag-PTS1 not yet imported into 
peroxisomes. As the intensity of the background levels correlates with the expression levels of 
HaloTag-PTS1 (Figure 4.1.B), the second possibility appears most likely. To investigate 
whether the employed cell-permeable HaloTag ligands label only newly synthesized 
HaloTag-PTS1 proteins in the cytosol or also pre-existing HaloTag-PTS1 proteins already 
located within peroxisomes, we pretreated CHO cells expressing HaloTag-PTS1 with 
cycloheximide six hours before and during the pulse-labeling. As these experiments did not 
yield a peroxisomal staining pattern (Figure 4.1.C, left panels), it can be concluded that the 
peroxisomal membrane – unlike the plasma membrane – is not permeable for the employed 
HaloTag ligands (only the data obtained with the HaloTag TMR ligand are shown). To 
completely exclude the possibility that this conclusion might be wrong as a result of inherent 
differences in the time scale of the labeling pulse, a similar condition was used to investigate 
the staining pattern of the amino-terminally anchored peroxisomal membrane protein 
Pex3p [29] containing a C-terminal HaloTag. As expected, cells expressing this fusion protein 
yielded a peroxisomal staining pattern (Figure 4.1.C, right panels). In summary, these 
experiments demonstrate that the punctate HaloTag-PTS1 signals in Figure 4.1.B represent 
proteins that were not yet imported into peroxisomes before pulse-labeling. 
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Interestingly, 80 to 90 percent of all peroxisomes contained the HaloTag-PTS1 protein. This 
observation indicates that peroxisomes, within the time frame of pulse-labeling (in casu 
16 hours), are – at least temporarily – matrix protein import-competent or able to exchange 
their protein content with import-competent organelles. In addition, depending on the 
turnover rate of peroxisomes under the employed experimental conditions, we can not 
exclude that the HaloTag-PTS1-containing organelles arise individually by fission from a 
matrix protein import-competent pre-peroxisomal template structure. In order to distinguish 
between these possibilities, we employed the HaloTag technology to visualize and study 
different generations of peroxisomes in individual mammalian cells (see below). 
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Figure 4.1. (previous page) Peroxisomal targeting of HaloTag fusion proteins 
(A,B) Transiently transfected wild-type CHO cells (WT) or Pex5-/- mouse fibroblasts (5-/-) expressing HaloTag 
(H) or HaloTag-PTS1 (H-PTS1) were, 24 hours posttransfection, cultured in the presence of HaloTag 
R110Direct (R110) or HaloTag TMR (TMR) ligand. After 16 hours (long-term labeling), the cells were 
processed for immunostaining with antibodies specific to Pex14p, followed by Texas Red or 
Alexa488-conjugated secondary antibodies. (C) CHO cells transiently expressing H-PTS1 or 
Pex3p(1-230)-HaloTag (3-H) were – 45 hours posttransfection – cultured in the presence of 100 µg/ml 
cycloheximide. After 6 hours, the TMR ligand was added for 30 minutes (rapid labeling), and the cells were 
processed for immunostaining with antibodies specific to Pex14p as described above. The nuclei were 
counterstained with DAPI (blue). Scale bars represent 10 µm. 
 
 
4.2. Visualization of distinct peroxisome populations in individual mammalian cells 
In order to gain more insight into the protein import competence of peroxisomes during their 
ageing process, CHO cells transiently expressing HaloTag-PTS1 were sequentially 
pulse-labeled with different HaloTag ligands. The rationale behind this approach was that – if 
the import competence of a peroxisome changes during its life span – this might be visualized 
by differences in the subcellular localization of HaloTag-PTS1 protein pools synthesized at 
different times. Obviously, this argumentation is only valid in case peroxisomes do not 
exchange their protein content and/or multiply by growth and symmetrical fission. 
Interestingly, our results show that the HaloTag-PTS1 pool synthesized within the first 
44 hours after transfection and the pool synthesized between 68 and 80 hours posttransfection 
displayed both an overlapping and a distinct distribution pattern (Figure 4.2.). This 
observation points towards an age-related heterogeneity in the peroxisomal population of an 
individual cell with respect to their capacity to incorporate newly synthesized matrix proteins. 
In this context, it is interesting to note that the peroxisomal membrane protein Pex14p, a 
central component of the peroxisomal matrix protein import machinery, seems to be less 
abundant in aged peroxisomes than in younger ones (Figure 4.2.B). Also, as the fluorescent 
signal intensities of the TMR-labeled HaloTag-PTS1 proteins do not proportionally decrease 
with the increase in number of new peroxisomes (data not shown), these organelles do not 
appear to multiply exclusively by symmetric fission. Finally, as both HaloTag-PTS1 pools – 
which were synthesized at different time points – display a considerable overlap in subcellular 
localization, it is unlikely that the HaloTag-PTS1-containing vesicles represent mature 
peroxisomes which arose individually by fission from a matrix protein import-competent 
pre-peroxisomal template structure. 
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Figure 4.2. Visualization of different peroxisome populations by employing the HaloTag technology 
(A) CHO cells, transiently transfected with a plasmid encoding HaloTag-PTS1 (H-PTS1), were sequentially 
incubated with the red-fluorescent HaloTag TMR (TMR) ligand (0-44 hours posttransfection), the non-
fluorescent HaloTag biotin ligand (44-68 hours posttransfection), and the green-fluorescent HaloTag R110Direct 
(R110) ligand (68-80 hours posttransfection). Afterwards, the cells were fixed and processed for immunostaining 
with anti-Pex14p antibodies, followed by an Alexa350-conjugated secondary antibody (blue). Scale bars 
represent 10 µm. (B) Enlargement of the outlined regions in panel A. 
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4.3. Peroxisomes do not exchange their protein content 
Our observation that the peroxisome population of an individual cell displays some 
heterogeneity with respect to their capacity to incorporate newly synthesized matrix proteins 
(Figure 4.2.), suggests that peroxisomes do not exchange their matrix protein content. 
However, in order to exclude the possibility that the lack of matrix protein content exchange 
might be an inherent property of old peroxisomes, CHO cells expressing HaloTag-PTS1 were 
labeled with the HaloTag TMR ligand and subsequently fused with cells stably expressing 
Pex14p-EGFP. This experiment revealed that – after three hours – the vast majority of all 
red-labeled peroxisomes became dually colored (Figure 4.3.). This observation was even 
more pronounced after 30 hours. On the other hand, a considerable number of peroxisomes 
were only marked with the green fluorescent fusion protein (Figure 4.3.). Combined, these 
observations indicate that the pool of pulse-labeled HaloTag-PTS1-containing peroxisomes is 
still able to import newly synthesized Pex14p-EGFP but does not mix its matrix protein 
content with the pool of pre-existing peroxisomes labeled with Pex14p-EGFP. This 
conclusion is further supported by our observation that there was no spatial overlap of the red 
and green fluorescent signals when the fused cells were grown in the presence of the protein 
synthesis inhibitor cycloheximide. Interestingly, the latter observation shows that also the 
pool of Pex14p-EGFP, a peroxisomal membrane protein, is not exchanged between 
peroxisomes. Finally, when two sets of CHO cells transiently expressing HaloTag-PTS1 were 
labeled with different fluorescent ligands, no color mixing was observed after cell fusion (data 
not shown). Note that it has already been shown that the mitochondrial matrix protein content 
in cell hybrids is mixed within one hour after fusion [30]. 
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Figure 4.3. Peroxisomes do not exchange their matrix protein content 
CHO cells, transiently transfected with a plasmid encoding HaloTag-PTS1 (H-PTS1), were labeled with the 
red-fluorescent HaloTag TMR ligand, washed, and co-cultivated overnight with CHO cells stably expressing 
Pex14p-EGFP (14-EGFP). Afterwards, the cells were fused with PEG and cultivated in the absence or presence 
of 100 µg/ml cycloheximide. The cells were then processed for fluorescence analysis at the indicated time 
points. Scale bars represent 10 µm. 
 
 
4.4. HaloTag-PTS1-labeled peroxisomes remain PMP import-competent 
As the experiments reported above clearly show that newly synthesized Pex14p, an integral 
membrane protein involved in matrix protein import, can be recruited to pre-existing 
peroxisomes (Figure 4.3.), we wondered whether or not the same is true for Pex16p, an 
integral membrane protein involved in PMP import. Therefore, CHO cells expressing 
HaloTag-PTS1 were labeled with the HaloTag TMR ligand, and – after removal of the 
ligand – transfected with a plasmid encoding Pex16p-EGFP. Our results show that almost all 
TMR-labeled peroxisomes remained Pex16p import-competent (Figure 4.4.A), strongly 
indicating that this peroxin exerts its primary function at the peroxisomal membrane. 
Interestingly, attempts to perform similar experiments by transfecting cells containing 
TMR-labeled Pex16p-HaloTag with a plasmid encoding EGFP-PTS1 were not successful. 
The reason for this was that virtually all Pex16p-HaloTag signals disappeared within 36 hours 
post-labeling (Figure 4.4.B). A probable explanation might be that the HaloTag, which is 
oriented to the cytoplasmic face of the peroxisomal membrane (data not shown), is degraded 
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by cytosolic proteases. Alternatively, the stability of Pex16p may be different from the one 
observed for HaloTag-PTS1, a peroxisomal matrix marker. In order to distinguish between 
these possibilities, CHO cells expressing Pex16p-HaloTag were (i) pulse-labeled with the 
HaloTag TMR ligand, cultivated in the absence or presence of the proteasome inhibitor 
MG132 (or epoxomicin; data not shown), and then chase-labeled again with the HaloTag 
R110Direct ligand, or (ii) cultivated in the absence or presence of MG132 and then processed 
for immunoblotting. These experiments clearly showed that a treatment with proteasome 
inhibitor markedly increased the stability of Pex16p-HaloTag (Figures 4.4.B-C and 4.5.B). 
Similar results were obtained for Pex3p-HaloTag (Figures 4.4.B-C and 4.5.B). Note that the 
abnormal accumulation of Pex16p (and to a lesser extent also Pex3p) frequently caused 
peroxisome clustering (Figure 4.4.C). Interestingly, the expression levels of the peroxisomal 
membrane protein Pex14p (Figures 4.4.C and 4.5.C) and the peroxisomal matrix protein 
catalase (Figure 4.5.D) were hardly affected upon MG132 treatment. In summary, these 
observations indicate that the half-lives of the peroxisomal membrane proteins Pex3p and 
Pex16p strikingly differ from the one observed for the peroxisomal matrix marker protein. 
This conclusion is in line with recent reports showing that photoactivatable GFP-SKL is a 
long-lived protein [12] and 35S-Flag-Pex3p-HA has – depending on the expression levels of 
Pex19p – an apparent half-life of two to six hours [31]. 
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Figure 4.4. (previous page) Protein import competence and signal stability of HaloTag-labeled 
peroxisomes 
CHO cells – transfected with a plasmid encoding HaloTag-PTS1 (H-PTS1), Pex16p-HaloTag (16-H), or 
Pex3p(1-230)-HaloTag (3-H) – were pulse-labeled with the red-fluorescent HaloTag TMR (TMR) ligand. Next, the 
cells were washed and either (A) transfected with a plasmid coding for Pex16p-EGFP (16-EGFP) or (B,C) 
sequentially chase-labeled with the non-fluorescent HaloTag biotin (biotin) ligand and the green-fluorescent 
HaloTag R110Direct (R110) ligand in the absence (panel B) or presence (panel C) of 5 µM MG132. Afterwards, 
the cells were fixed and processed for immunostaining with antibodies specific to Pex14p, followed by an 
Alexa350-conjugated secondary antibody. Representative images are shown. Scale bars represent 10 µm. 
 
 
 
 
 
 
Figure 4.5. Steady state concentrations of peroxisomal reporter proteins prior and after MG132 addition 
CHO cells, transiently transfected with a plasmid coding for Pex3p(1-230)-HaloTag (3-H) or Pex16p-HaloTag 
(16-H), were – 24 hours posttransfection – cultivated in the absence (-) or presence (+) of 5 µM MG132. After 
16 hours, total cell extracts were prepared and equal amounts of extracts were subjected to SDS-PAGE and 
blotted onto nitrocellulose membranes. (A) Ponceau S was used to visualize the total protein pattern. After 
destaining, the blots were processed for immunostaining with antibodies specific for (B) the HaloTag, 
(C) Pex14p, or (D) catalase. The arrows indicate the migration of the full-length proteins. The arrowheads mark 
the 3-H and 16-H degradation products. The asterisk indicates the migration of a non-specific, immunoreactive 
protein. The migration of the relevant molecular mass markers (expressed in kDa) is shown at the left. 
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4.5. Turnover rate of peroxisomes in cultured mammalian cells 
Our observation that peroxisomes do not appear to multiply simply by growth and 
symmetrical fission (Figure 4.2.) enabled us to label the pool of protein import-competent 
peroxisomes and determine their turnover rate. The results of two representative experiments 
are shown in Figure 4.6. A quick visual analysis shows that – immediately after removal of 
the unbound ligand (day 0) – the vast majority of peroxisomes contain fluorescently labeled 
HaloTag-PTS1, and that the percentage of labeled organelles decreases steadily over time 
with at the final time point (day 9) only a few HaloTag-labeled dots discernible 
(Figure 4.6.A). A quantification and graphical analysis of these results revealed a biphasic 
pattern (Figure 4.6.B): during the first two days, a stability or even slight increase in the 
percentage of labeled peroxisomes was observed; afterwards, this number displayed an 
exponential decay with a half-life of approximately two days (Figure 4.6.B). Importantly, this 
pattern was consistent and ligand independent. The initial stability or increase in the 
percentage of HaloTag-labeled peroxisomes might be explained by two distinct effects which 
are not necessarily mutually exclusive: (i) the uptake of cytosolically-localized labeled 
HaloTag-PTS1 proteins into pre-peroxisomal template structures (see above); and (ii) a 
limited number of symmetrical fission events occurring within the pool of labeled 
peroxisomes (see below). The exponential decay rates observed in the second part of the 
graphs point toward a peroxisomal half-life of approximately two days. This corresponds to a 
daily fractional peroxisomal turnover rate of approximately 30 percent. 
 
 
 
 
 
 
Figure 4.6. (next page) Peroxisome turnover in cultured mammalian cells 
CHO cells, transiently transfected with a plasmid encoding HaloTag-PTS1 (H-PTS1), were – 24 hours 
posttransfection – cultured in the presence of HaloTag R110Direct (R110) or HaloTag TMR (TMR) ligand. 
After 12 hours (= day 0), the cells were further cultivated for the indicated times before being processed for 
immunostaining with antibodies specific to Pex14p, followed by a secondary antibody (the Texas Red-conjugate 
is shown). (A) Fluorescence images from a representative experiment. The nuclei were counterstained with 
DAPI (blue). Scale bars represent 10 µm. (B) Quantification of the HaloTag-PTS1 protein labeling. The number 
of HaloTag-PTS1-labeled peroxisomes per cell was quantified and expressed as a percentage of the total number 
of peroxisomes (as visualized by staining for Pex14p). At least 15 cells were analyzed per condition. The 
average number (± standard deviation) of total peroxisomes per cell section was 297 (± 182) and 302 (± 171) for 
the experiments in which the R110 (left panel) and TMR (right panel) ligand were used, respectively. 
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4.6. Peroxisome degradation under basal conditions occurs via an autophagy-related 
mechanism 
 
To investigate the role of autophagy in peroxisome degradation under basal metabolic 
conditions, we performed a HaloTag-PTS1 labeling experiment and compared the turnover 
rates of the labeled organelles in the absence and presence of 3-methyladenine (3-MA), a 
compound widely used to block the autophagic degradation pathway [32]. From this 
experiment, it was clear that inhibition of autophagy with 3-MA resulted in an impaired 
turnover of peroxisomes (Figure 4.7.A). Interestingly, changing the physiological levels of 
autophagy also affected the cell size. To document these observations in an objective manner, 
all changes were quantified over time (Figure 4.7.B-E). This analysis did not only confirm our 
key observation that peroxisome degradation under basal conditions occurs via an 
autophagy-related mechanism (Figure 4.7.B), but also highlighted two other interesting 
findings: (i) the absolute number of labeled peroxisomes keeps steadily increasing in the 
presence of 3-MA (average increase per day: 15%), even after a period of two days after 
removal of the unbound ligand (Figure 4.7.C); and (ii) this increase does not match the 
increase in total peroxisome number (average increase per day: 30%) (Figure 4.7.D). The first 
finding provides strong evidence that HaloTag-labeled peroxisomes can be formed by fission 
from pre-existing labeled organelles. The second finding indicates that in general the matrix 
protein content of pre-existing organelles is not evenly distributed over new organelles. This 
implies that peroxisome fission is a non-symmetrical process or that new peroxisomes arise 
de novo. Finally, it is important to note that our results obtained with 3-MA exclude the 
possibility that the ‘disappearance’ of pulse-labeled peroxisomes is an artifact caused by 
intraperoxisomal proteolytic cleavage of the fluorescently labeled reporter protein [33]. 
 
 
Figure 4.7. (next page) Peroxisome degradation is inhibited by 3-methyladenine, an inhibitor of 
autophagosome formation 
CHO cells, transiently transfected with a plasmid encoding HaloTag-PTS1 (H-PTS1), were – 24 hours 
posttransfection – labeled with HaloTag R110Direct (R110) ligand. After 12 hours (= day 0), the cells were 
further cultivated for the indicated times in the absence (-, grey bars) or presence (+, black bars) of 10 mM 
3-methyladenine (3-MA) before being fixed and processed for immunostaining with antibodies specific to 
Pex14p, followed by a Texas Red-conjugated secondary antibody. (A) Fluorescence images from a 
representative experiment. The nuclei were counterstained with DAPI (blue). Scale bars represent 10 µm. 
(B-E) Quantification of the results. At least 15 cells were analyzed per condition. Mean and standard deviations 
are shown. 
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5. DISCUSSION 
In this study, we employed the HaloTag technology to further our understanding of how 
peroxisomes are formed and degraded in mammalian cells. This reporter protein technology, 
which is technically easier and requires less sophisticated equipment than in cellula 
pulse-chase imaging protocols with photoactivatable GFP [12], enabled us to optically 
distinguish separate pools of the same peroxisomal reporter protein synthesized at different 
time points within individual cells. The results obtained from this approach are discussed 
below. 
 
In a first series of experiments, we obtained evidence that peroxisomes display an age-related 
heterogeneity with respect to their capacity to incorporate newly synthesized proteins. At first 
sight, this result appears to contradict previous observations that virtually all peroxisomes are 
protein import-competent [34]. However, a careful examination revealed that comparable data 
were obtained within similar time frames: we found that – at any time – 80 to 90 percent of 
the total peroxisome population was protein import-competent; and Hill and Walton (1995) 
reported that ‘few’ peroxisomes did not contain sufficient reporter protein to render them 
visible by immunofluorescence microscopy. In summary, these experiments indicate that 
(i) the capacity to import proteins is not restricted to newly developed peroxisomes, and 
(ii) the peroxisomal protein import machinery is most likely only compromised in organelles 
containing (age-related) defects. As this subclass of peroxisomes represents only a minor 
percentage of the total peroxisome fraction, these organelles are most likely quickly degraded 
by an autophagy-related mechanism (see below). 
 
It is well-known that in healthy cells mitochondria continually divide and fuse to form a 
dynamic interconnecting network [35]. As (i) it is currently not clear whether or not 
peroxisomes in mammalian cells are able to exchange their protein content, and (ii) such 
information is critical to properly interpret the results of our pulse-chase experiments, we 
developed an in vivo assay to study peroxisomal content mixing. Interestingly, we could not 
find any evidence indicating that peroxisomes also form such a dynamic network. Similar 
observations have recently been reported for yeast peroxisomes [10]. Note that our findings 
do not establish absolute proof that proteins other than the ones investigated can not be 
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exchanged between peroxisomes. However, they are in line with the observation that, 
although peroxisomes and mitochondria share the same fission machinery [1], key 
components of the mitochondrial fusion machinery have not yet been identified in 
peroxisomes. Our finding that peroxisomes do not fuse in vivo also implies that the 
interconnected peroxisomes in partially differentiated cells of the mouse preputial gland are 
the result of lack of fission, rather than fusion [36]. 
 
Although it is well documented that in mammals macroautophagy is playing a major role in 
the specific degradation of excess peroxisomes [37], the functional significance of this 
degradation pathway in the removal of peroxisomes under basal conditions is unclear. In this 
study, we showed that the half-life of peroxisomes in cultured mammalian cells is 
approximately two days. This observation is pretty close to the time of 1.5 days determined in 
rat liver by isotopic labeling measurements [38]. We also provide evidence that peroxisome 
degradation under basal conditions predominantly occurs via an autophagy-related process. 
As it is well-known that the employed inhibitor (in casu 3-MA) blocks autophagosome 
formation by inhibiting the class III phosphoinositide 3-kinase (PI(3)K) complex [32], the 
most likely mechanism is macroautophagy. However, as (i) PI(3)K is required for both 
macro- and microautophagic degradation of peroxisomes in yeasts [6], (ii) 3-MA may also 
slow down lysosomal degradation [39], and (iii) previous studies suggested that peroxisomes 
are degraded by microautophagy in CHO cells [15], our findings can only be used as a first 
indication that macroautophagy is involved. Previously, it has been suggested that – under 
normal physiological conditions – peroxisomes are destroyed in a completely random 
way [38]. However, as (i) it is unlikely that a cell will ‘randomly’ eliminate newly 
synthesized functional organelles, and (ii) the number of protein import-incompetent 
peroxisomes only represents a minor percentage of the total peroxisome fraction, we believe 
that only functionally compromised organelles are marked for degradation. Note that this 
hypothesis – albeit not yet proven – is in line with the recent observation that the expression 
of ubiquitinated PMPs resulted in the p62-dependent targeting of peroxisomes to 
autophagosomes in mammalian cells [18]. Which endogenous ubiquitinated PMPs may 
trigger peroxisome degradation in vivo is not yet clear. 
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An intense debate in the peroxisome field is how these organelles are formed. According to 
the original notion, peroxisomes are formed by growth and fission of pre-existing ones [7]. 
This view changed when new evidence demonstrated that peroxisomes predominantly arise 
de novo from specialized regions of the endoplasmic reticulum [9,12,40,41]. However, some 
recent studies tend to favor again the growth and division model, and conclude that – at least 
in growing wild-type cells – the ER only contributes membrane material to pre-existing 
peroxisomes which grow and divide [10,11,31,42,43]. Our observation that the absolute 
number of pulse-labeled peroxisomes keeps steadily increasing when autophagy is blocked 
clearly shows that pre-existing peroxisomes can multiply by fission. However, the fact that 
this increase does not match the increase in total peroxisome number – which equals the daily 
fractional peroxisomal turnover rate of approximately 30 percent – implies that the matrix 
protein content of pre-existing organelles is not evenly distributed over new peroxisomes. 
This finding suggests that new peroxisomes are formed by a non-symmetrical fission process 
or that peroxisomes arise de novo and not from pre-existing peroxisomes. Unfortunately, our 
current findings do not allow us to unambiguously distinguish between these possibilities 
which are not necessarily mutually exclusive. However, our combined findings that (i) at any 
time 80 to 90 percent of the total peroxisome population is matrix protein import-competent, 
(ii) pre-existing HaloTag-PTS1-labeled peroxisomes remain Pex3p, Pex14p, and Pex16p 
import-competent, and (iii) peroxisomes do not fuse and mix their protein content, make it 
highly unlikely that ‘new’ peroxisomes arise primarily de novo from the ER or any other 
pre-peroxisomal template. In this context, it is also interesting to note that in regenerating rat 
liver some peroxisomes with marked differences in D-amino acid oxidase activities have been 
reported to be interconnected via narrow 30-50 nm hourglass-shaped bridges, indicating that 
they originate from the same parent organelle by non-symmetrical fission [44]. In addition, it 
has been reported that the matrix protein content of Hansenula polymorpha peroxisomes is 
generally unevenly distributed over the resulting organelles upon fission [11]. One possibility 
is that the non-symmetric fission events represent a quality control mechanism in which 
dysfunctional peroxisomal proteins are retained within the mother organelle, which – after a 
limited number of fission events – is targeted for degradation. 
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Our observation that HaloTag-PTS1-containing peroxisomes are still Pex16p 
import-competent as well as the recent finding that Pex16p exerts its function as receptor for 
cytosolic Pex3p-Pex19p complexes at the peroxisomal membrane [31], contrast sharply with 
some data published by Kim et al. [12]. Indeed, according to these authors, newly synthesized 
Pex16p is first inserted into the ER where it recruits other components essential for 
peroxisome biogenesis (e.g. Pex3p), and this would then result in the differentiation of a 
‘peroxisome-like’ domain in the ER that eventually would detach from the ER and transform 
into a nascent mature peroxisome [12]. At present, it is not clear whether these apparently 
conflicting data represent condition-specific characteristics. However, it should be mentioned 
that the study performed by Kim et al. [12] suffers from the potentially flawed assumption 
that daughter peroxisomes formed by division of pre-existing peroxisomes should all contain 
peroxisomal components (in casu photoactivatable GFP-PTS1) from their mother 
peroxisomes. In addition, it is known that photobleaching and photoactivation require 
relatively high expression levels of the tagged protein (in casu photoactivatable Pex16p-GFP) 
to provide a sufficient signal-to-noise ratio [45], a condition which in our hands results in 
peroxisome clustering. 
 
In this study, we report the development of a simple method to study peroxisome dynamics in 
cultured mammalian cells. In summary, we showed that 80 to 90 percent of all peroxisomes 
are protein import-competent, and that the matrix content of pre-existing peroxisomes is not 
evenly distributed over new peroxisomes. The latter observation can be interpreted by either 
of two quite different hypotheses. The first one is that new peroxisomes are formed de novo 
from the ER or another pre-peroxisomal template. The second one is that peroxisomes 
generally multiply by growth and non-symmetrical fission events. Although the first 
hypothesis can not be excluded, we favor the second, in view of our observations that 
virtually all pre-existing peroxisomes remain import-competent for Pex3p and Pex16p, two 
peroxins identified as essential factors for PMP assembly [46]. We also demonstrated that the 
half-life of the peroxisomal matrix protein content is approximately two days, and that 
autophagy is the preferred mechanism for the degradation of (dysfunctional) peroxisomes 
under basal conditions. In addition, we provide evidence that the turnover rate of Pex3p and 
Pex16p is much faster than that of matrix proteins, and that the half-life of these proteins can 
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be extended by inhibiting the proteasome degradation pathway. Finally, as peroxisomes do 
not mix their protein content, we hypothesize that a non-symmetrical division process may act 
as a quality control mechanism in which dysfunctional peroxisomal proteins are retained 
within the mother organelle, which – after a limited number of fission events – is targeted for 
autophagic degradation. A central research question that will guide our future studies is how 
damaged and non-functional peroxisomes are specifically recognized for sequestration. 
Gaining a better insight into this topic is an essential prerequisite to comprehend the 
molecular mechanisms underlying diseases linked to peroxisomes and the removal of 
organelles during physiological and pathological processes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure. (next page) Schematic overview of the HaloTag protein-mediated pulse-labeling 
strategy used to visualize peroxisomes in living cells 
Mammalian cells transiently transfected with a plasmid coding for a fusion protein between the HaloTag (H) and 
PTS1, Pex3p (3) or Pex16p (not shown) were incubated (either alone or sequentially) with the HaloTag 
R110Direct (502Ex/527Em) or HaloTag TMR (555Ex/585Em) ligand. After each labeling reaction, the cells were 
extensively washed and subjected to live cell imaging or fixed and processed for (immuno)fluorescence 
microscopy. The employed HaloTag ligands are cell-permeable and consist of a fluorescent label and a 
chloroalkane linker. The mechanism of how these ligands are transported across the plasma membrane is 
currently unknown. However, once these ligands enter the cell, they irreversibly bind to the HaloTag protein. 
The formation of this covalent bond (represented by a peripheral blue circle) occurs rapidly under general 
physiological conditions. Importantly, the unbound ligands can not freely cross the peroxisomal membrane (see 
Figure 4.1.C). This implies that the labeling of peroxisomal HaloTag fusion proteins can only occur when the 
HaloTag is exposed to the cytosolic surface of the peroxisomal membrane or before newly synthesized proteins 
are translocated across the peroxisomal membrane. A substantial advantage of this technology is that distinct 
pools of proteins, generated from a single genetic HaloTag-encoding construct, can be visualized at different 
wavelengths. For example, the diagram shows a sequential labeling strategy for HaloTag-PTS1 (a reporter 
protein that is translocated across the peroxisomal membrane through the docking-translocation machinery 
(DTM) in a Pex5p (5)-dependent manner) and Pex3p-HaloTag (an amino-terminally anchored peroxisomal 
membrane protein). Note that (i) the green and red lines represent the potential transport pathways of the first (1) 
and second (2) HaloTag ligand, respectively, (ii) the unbound ligands are rapidly removed upon extensive 
washing (the unbound green ligand employed for the first pulse-labeling is only shown to demonstrate that these 
molecules are quickly exported out of the cell), and (iii) it has already been reported that the efflux of rhodamine 
analogues is mediated by the multidrug resistance protein ABCB1 [47]. 
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1. INTRODUCTION 
The data presented in the previous chapter clearly show that the HaloTag Interchangeable 
Labeling technology (Promega) – allowing the specific pulse-labeling of proteins in living 
cells [1] – is a useful and straightforward approach to study peroxisome dynamics in cultured 
mammalian cells. Through the sequential pulse-labeling of a peroxisomal matrix reporter 
protein synthesized at different time points, we could visualize distinct peroxisome 
populations within the same cell. In-depth microscopic analyses resulted in some interesting 
findings regarding peroxisomal matrix protein import, the half-life of specific peroxisomal 
proteins, and peroxisome turnover (see Chapter IV) [2]. In this chapter, we report some 
additional unpublished HaloTag-related data with respect to (i) the pore-forming properties of 
the peroxisomal membrane in vivo, (ii) the isolation of peroxisome populations enriched in 
‘old’ and ‘young’ organelles, and (iii) the potential role of Pex14p in peroxisome degradation 
in mammalian cells. 
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2. MATERIALS AND METHODS 
2.1. Plasmids 
The restriction enzymes were purchased from TaKaRa. The oligonucleotides used in this 
study were synthesized by Eurogentec. Polymerase chain reactions were routinely performed 
using Pfx DNA polymerase (Invitrogen). Constructs were made by using standard molecular 
cloning techniques. Plasmid pJW5 (encoding HaloTag-PTS1) was obtained by cloning the 
coding sequence for HaloTag-PTS1, derived from the Bam HI/Not I-digestion of 
pMF1434 [2], into the Bam HI/Not I-digested pEGFP-N1 vector. pMF1631 (encoding 
HaloTag-Hscatalase) was constructed by cloning the Hind III/Bam HI-digested PCR product 
coding for the HaloTag reporter protein [template: pHT2; primers: pHT2fwHindIII 
(5’-GGGAAGCTTACCATGGGGTCCGAAATCGGTAC-3’) and pHT2rvBamHI 
(5’-GGGGGATCCGCCGCCGGCCAGCCCGGGGAG-3’)] and the Bgl II/Not I-digested 
PCR product coding for Hscatalase [template: pMF986; primers: HsCatalfwBglII (5’-
GGGAGATCTATGGCTGACAGCCGGGATCCC-3’) and HsCatalrvNotI (5’-
GGGGCGGCCGCTCACAGATTTGCCTTCTC-3’)] into the Hind III/ Not I-digested 
backbone fragment of pEGFP-N1 via a three-point ligation procedure. pMF1633 (encoding 
HaloTag-HsHAO2) [template: human liver cDNA library; primers: HsHAO2fw1 (5’-
GAGTGAATGTGAAGGTCC-3’) and HsHAO2rv1 (5’-CAGCAGTCTG GTTATTGGCCC-
3’); nested primers: HsHAO2fwBamHI (5’-GGGGGATCCATGTCCT TGGTGTGTCTG-3’) 
and HsHAO2rv1 (5’-CAGCAGTCTGGTTATTGGCCCAND-3’)] was generated in a similar 
way. pMF1634 (encoding HaloTag-HsAGT1) was constructed by cloning the Bgl II/Not I-
restricted PCR fragment [template: pMF1637; primers: HsAGTfwBglII (5’-
GGGAGATCTATGGCCTCTCACAAGCTGCTG-3’) and HsAGTrvNotI (5’-
GGGGGCGGCCGCTCACAGCTTCTTCTTGGGGCAG-3’)] into the Bam HI/Not I-digested 
backbone fragment of pMF1633. pMF1637 is a pETM11-derived plasmid containing the 
coding sequence of HsAGT1. 
 
2.2. Cell culture 
CHO cells and primary human fibroblasts were grown in MEMα under standard conditions 
(37°C, 5% CO2). CHO cell lines expressing HaloTag fusion proteins were – after transfection 
with polyethylenimine (PEI MW ~25 kDa; Sigma-Aldrich) [3] – enriched by growing the cells 
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in the presence of G418 (600 µg/ml; Sigma-Aldrich) for at least three weeks. To block 
proteasomal degradation, cells were treated with 5 µM MG132 (Sigma-Aldrich) or 5 µM 
epoxomicin (Calbiochem). 
 
2.3. Immunofluorescence microscopy 
Labeling of HaloTag fusion proteins has been described elsewhere [2]. The processing of cell 
samples for immunofluorescence microscopy has been described in detail in Chapter III. The 
rabbit polyclonal antiserum against HsPex14p has been described before [4]. The rabbit 
polyclonal antibody against PMP70 was purchased from Zymed. The sheep polyclonal 
antibody against PMP70 was kindly provided by Dr. E. Baumgart-Vogt (Justus-Liebig 
University, Gieβen, Germany). 
 
2.4. Flow cytometry 
Depending on the experiment, CHO cells expressing HaloTag-catalase were (i) pulse-labeled 
for 36 h with the HaloTag TMR or R110Direct ligand or (ii) sequentially pulse-labeled – i.e. 
labeling with the first ligand for 64 h, extensively washed with PBS, cultivated in standard 
growth medium for 56 h, and labeled with the second ligand for 24 h. Sixteen hours after 
removal of the ligand, cells were harvested, resuspended in cold homogenization buffer 
[(0.25 M sucrose, 5 mM MOPS (pH 7.2), 1 mM EDTA (pH 7.2), 0.1% (v/v) ethanol, 1 mM 
dithiothreitol, and a proteinase inhibitor mixture (Sigma)] and homogenized (20 strokes) by 
using a stainless steel tissue grinder (Kontes). The resulting homogenate was first subjected to 
a 100 x g spin for 5 min to remove intact cells, cell debris and nuclei. An organelle fraction 
was obtained by centrifugation of the postnuclear supernatant (i) at 20000 x g at 4°C for 
30 min or (ii) at 100000 x g at 4°C for 1 h on a Nycodenz step gradient [5]. The obtained 
fractions were analyzed by using fluorescence-activated cell sorting (FACS) with standard PE 
(phycoerythrin)- and FITC (fluorescein isothiocyanate)-filters (FACSVantage). Flow 
cytometric analyses were performed by Vik van Duppen (Department of Oncology, 
Hematology Section, K.U.Leuven, Belgium).  
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3. RESULTS 
3.1. Relocalization of peroxisomal matrix proteins upon inhibition of the proteasome 
system 
During earlier studies intended to characterize the turnover rates of the HaloTag-labeled 
peroxisomal membrane proteins Pex3p and Pex16p [2], we observed a remarkable 
phenomenon for the matrix reporter protein HaloTag-PTS1. Indeed, upon a 24 hour treatment 
with proteasome inhibitor, pulse-labeled HaloTag-PTS1 proteins already imported into 
peroxisomes, were leaking out of the peroxisome lumen and partially relocated to the nucleus 
(Figure 5.1.). Note that we have recently demonstrated that culturing cells in the presence of 
proteasome inhibitor blocked the PTS1 import pathway in vivo [6]. However, in the present 
study the observed phenotype is not due to a defect in PTS1 import since – at the time of 
treatment – the majority of labeled PTS1-proteins already resided in peroxisomes. 
Importantly, the peroxisomal membrane protein Pex14p displayed a normal peroxisomal 
staining pattern under the conditions employed (Figure 5.1.). Based on these findings, we 
hypothesize that – upon treatment with proteasome inhibitor – a (non-regulated) pore is 
formed in the peroxisomal membrane. Such a pore may represent a blocked intermediate of 
the postulated transient pore structure involved in the translocation of matrix proteins across 
the peroxisomal membrane [7]. However, until now, this pore has not yet been characterized 
on the molecular level. 
 
In order to characterize this pore-like structure, we determined whether or not it displayed 
selectivity for differently sized proteins. Therefore, we analyzed the behavior of four 
peroxisomal matrix reporter proteins of various size, namely HaloTag-PTS1 (monomer of 
33 kDa), HaloTag-AGT1 (putative dimer of 169 kDa), HaloTag-HAO2 (putative tetramer of 
286 kDa), and HaloTag-catalase (putative tetramer of 364 kDa). We observed that after 
blocking the proteasome system by treatment of the cells with epoxomicin (5 µM) or MG132 
(5 µM; data not shown), the smaller matrix proteins (i.e. HaloTag-PTS1 and HaloTag-AGT1) 
were leaking out while the larger ones (i.e. HaloTag-HAO2 and HaloTag-catalase) were 
retained within peroxisomes (Figure 5.1.). Remarkably, HaloTag-PTS1 and to a lesser extent 
HaloTag-AGT1, specifically relocalized to the nucleoli, a phenomenon that has also been 
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discerned for the cytoplasmically localized HaloTag reporter protein itself (data not shown). 
In conclusion, these data suggest the formation of a size-dependent pore structure in the 
peroxisomal membrane upon treatment of cells with proteasome inhibitor. 
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Figure 5.1. Relocalization of pulse-labeled peroxisomal matrix proteins upon treatment with proteasome 
inhibitor depends on their size 
CHO cells expressing HaloTag-PTS1 (A), HaloTag-AGT1 (B), HaloTag-HAO2 (C), or HaloTag-catalase (D) 
were pulse-labeled with the HaloTag TMR ligand (1 µM) for 16 hours. After removal of the ligand, the cells 
were extensively washed and incubated for 3 hours in standard growth medium. Subsequently, cells were treated 
for 24 hours with the proteasome inhibitor epoxomicin (+) or DMSO (-). The cells were fixed and stained with 
antibodies specific for the peroxisomal membrane protein Pex14p and Alexa Fluor 488-conjugated secondary 
anti-rabbit antibodies. Nuclei were visualized by DAPI-staining. Scale bars represent 10 µm. 
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3.2. Flow cytometric analysis of subcellular fractions containing differentially labeled 
peroxisome populations 
The HaloTag technology provides an elegant tool to visualize different populations of 
peroxisomes within the same cell [2]. Since the oldest peroxisomes loose their matrix protein 
import competence, they are only labeled during the first pulse, while the youngest 
peroxisomes just contain HaloTag proteins synthesized during the second pulse. We 
attempted to sort both populations by flow cytometry in order to characterize them at the 
biochemical level. CHO cells enriched for HaloTag-catalase were used. Preliminary studies 
showed that a mixture of two cell populations containing red (TMR)- or green 
(R110Direct)-labeled peroxisomes could be sorted by fluorescence-activated cell sorting 
(Figure 5.2.C). Next, we performed pulse-chase experiments in which the HaloTag matrix 
reporter protein was first labeled with TMR ligand and subsequently with R110Direct ligand 
or vice versa. Fractions enriched for peroxisomes were obtained by separation of a 
postnuclear supernatant on a Nycodenz step gradient (Figure 5.2.A) [8]. Microscopic analysis 
of the organellar fraction confirmed the presence of red- and green-labeled peroxisomes 
(Figure 5.2.B). Interestingly, the populations showed a clear difference in abundance, i.e. the 
number of peroxisomes that were labeled with the first ligand was significantly lower in 
comparison to the number of peroxisomes labeled with the second ligand (Figure 5.2.B). 
Moreover, peroxisomes could – based on their fluorescence spectrum – be classified in ‘old’, 
‘middle-aged’, and ‘young’ organelles (Figure 5.2.B). However, the populations could not be 
distinguished from each other by flow cytometry. Similar results were obtained for 
peroxisome populations isolated from a mixture of cells each containing red- or green-labeled 
peroxisomes (Figure 5.2.D). A likely explanation for these observations could be obtained by 
the flow cytometric analysis of a mixture of microparticles of heterogeneous size (0.5 µm, 
0.9 µm, and 3.0 µm). Remarkably, particles of 0.9 µm and 0.5 µm – corresponding to the size 
of peroxisomes – were difficult to separate (Figure 5.2.F). Further evidence that size 
constraints are indeed the main reason for the lack of separation was provided by the fact that 
the mixture of cells containing red- or green-labeled peroxisomes – upon lysis with 
Triton X-100 – yielded a similar output display as the one obtained for the peroxisomal 
fractions, and which can be considered as ‘background scatter’ (Figure 5.2.E). From these 
experiments we can conclude that differently labeled populations of peroxisomes 
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(size: 0.3-1.0 µm) – unlike mitochondria (size 0.5-5.0 µm) [9] – can currently not be 
separated by FACS. 
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Figure 5.2. Flow cytometry data of HaloTag-labeled cells and peroxisomes 
(A) Representative blots of fractions from CHO cells which are isolated according to a procedure routinely used 
to obtain peroxisome-enriched fractions from mammalian cells. Equivalent portions of the total cell lysate (L), 
the nuclear fraction (N), and the postnuclear fraction (P) and equal volumes of the gradient fractions (bottom 
fraction (B), top fraction (T)) were separated by SDS-PAGE and stained with Ponceau S (detection of total 
protein profile) or stained with antisera specific for Pex14p (peroxisomal integral membrane protein marker), 
catalase (peroxisomal matrix protein marker), glutamate dehydrogenase (GDH, mitochondrial protein marker), 
and cytochrome P450 4A (Cyt P450 4A, microsomal protein marker). The arrow marks the remainder of the 
bovine serum albumin that is still present after removal of the cell culture medium. Peroxisomal peak fractions 
are marked with an asterisk. The migration of the molecular mass markers (expressed in kDa) is indicated. Image 
adapted from Fransen et al., 2004 [8]. (B) CHO cells expressing HaloTag-catalase were sequentially labeled 
with the TMR (64 hours) and R110Direct ligand (24 hours) (right panels) or vice versa (left panels). An 
organelle fraction, which was obtained by loading a postnuclear fraction on a Nycodenz density gradient, was 
analyzed by fluorescence microscopy. Scale bars represent 20 µm. (C-F) Flow cytometry data. (C) Mixture of 
two CHO cell populations expressing HaloTag-catalase. One cell population was pulse-labeled (36 hours) with 
the TMR ligand (P4), the other one with the R110Direct ligand (P5). (D) Organelle fraction obtained by 
differential centrifugation of a cell mixture (same as in C) homogenate. (E) Cell mixture (same as in C) treated 
with Triton X-100 (1% (w/v) final concentration). (F) Mixture of microparticles with heterogeneous size 
(0.5 µm, 0.9 µm, and 3.0 µm). 
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3.3. Turnover of peroxisomal ghosts in the presence and absence of Pex14p 
In the methylotrophic yeast H. polymorpha, the presence of the N-terminal fragment of 
Pex14p has been shown to be required to target peroxisomes for pexophagy [10]. To 
investigate whether or not Pex14p has a similar role in mammalian cells, we analyzed 
Pex14p-deficient fibroblasts from a patient who was diagnosed with Zellweger 
syndrome [11]. We compared the number and morphology of peroxisomal remnants in 
Pex1p-, Pex14p-, or Pex26p-deficient human fibroblasts and could not observe any 
differences (data not shown). Notably, as peroxisomal ghosts were visualized by 
immunostaining for a peroxisomal membrane protein, no conclusions could be drawn 
regarding the turnover rate of these structures. To ascertain that Pex14p-containing ghosts and 
ghosts lacking this peroxin display similar turnover profiles, we intended to determine the 
turnover rate of these structures in various peroxin-deficient cell lines by using HaloTag-PMP 
fusion proteins. However, in the course of our experiments performed in wild-type 
mammalian cells, we observed that such reporter proteins are rapidly degraded in a 
proteasome-dependent manner [2]. Therefore, HaloTag-PMPs are not suitable to investigate 
the dynamics of peroxisomal ghosts. 
 
 
4. DISCUSSION 
The data presented in this chapter clearly show that pulse-labeled HaloTag-fusion proteins 
have the ability to diffuse out of the peroxisomal matrix in a size-dependent manner upon 
inhibition of the proteasome system. These observations sustain the transient pore model 
suggesting the presence of a transient pore structure in the peroxisomal membrane through 
which proteins can enter the peroxisome lumen during matrix protein import [7]. 
Interestingly, the PTS1 import receptor Pex5p has been proposed as a plausible pore-forming 
protein since (i) a considerable portion of the membrane-bound fraction of Pex5p behaves as 
an intrinsic membrane protein [12], (ii) Pex5p has been shown to be present in high molecular 
weight complexes at the peroxisomal membrane [13], (iii) recombinant Pex5p has the ability 
to insert spontaneously into phospholipid membranes [14], (iv) Pex5p inserts into the 
peroxisomal membrane in an ATP-independent manner, similar to pore-forming toxins, and 
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(v) Pex5p passes the peroxisomal membrane during its cycle of matrix protein import [15]. 
The latter process involves monoubiquitination of Pex5p which is necessary to recycle the 
receptor from the peroxisomal membrane to the cytosol [15]. In this context, it has been 
hypothesized before that blocking the proteasome system depletes the cell from free ubiquitin, 
which results in trapping of the PTS1-receptor Pex5p on the peroxisomal membrane and 
inhibition of peroxisomal matrix import (for more details: see 2.2.2. p.17) [6]. Altogether, 
Pex5p is one potential candidate responsible for the formation of a pore structure in the 
peroxisomal membrane. In future experiments, we will investigate the potential pore-forming 
capacity of Pex5p by using (i) a Pex5p RNA interference approach and (ii) Pex5(C11S)p, a 
Pex5p variant which can not be ubiquitinated and hence accumulates at the peroxisomal 
membrane [16]. 
 
In the second set of experiments, we attempted to separate differentially labeled peroxisome 
populations by flow cytometry as both populations could not be separated by density gradient 
centrifugation (Figure 5.2.A-B). Sorting ‘old’ and ‘young’ peroxisomes would be a very 
interesting tool to unravel the molecular and metabolic features of a peroxisome during 
different stages of its development. Recent data of Twig and collaborators concerning the life 
cycle of mitochondria indicate that the autophagic degradation of these organelles is no 
random process but depends on the mitochondrial membrane potential and fusion capacity 
(see 3.2.2. p.26) [17]. Presumably, ‘old’ peroxisomes also contain some specific markers that 
target the organelles for autophagy. However, our preliminary experiments regarding the 
fluorescence-based sorting of two peroxisomal populations were not successful due to 
technical limitations. 
 
Comparing the morphology and the number of peroxisomal ghosts in Pex14p-deficient and 
other peroxin-deficient cell lines did not provide any evidence for a potential role of Pex14p 
in peroxisome degradation in mammals. In addition, the use of pulse-labeled PMPs to 
determine the turnover rate of ghost structures is hampered by the rapid proteasomal 
degradation of the investigated membrane proteins. The latter makes it currently impossible to 
monitor a fluorescently-labeled peroxisomal remnant until the moment of its degradation. 
Apart from our earlier observation in wild-type cells that matrix import-incompetent 
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peroxisomes seem to have a reduced Pex14p content [2], we are currently not able to draw a 
conclusion regarding the turnover rate of peroxisomal ghosts and the role of Pex14p in the 
degradation of mammalian peroxisomes. 
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1. ABSTRACT 
BACKGROUND: Peroxisome biogenesis disorders are a clinically and genetically 
heterogeneous group of very severe autosomal recessive disorders caused by impaired 
peroxisome biogenesis. The prototype of this group of disorders is the cerebro-hepato-renal 
syndrome of Zellweger. METHODS AND RESULTS: Here we report a patient with 
Zellweger syndrome, who presented at the age of three months with icterus, dystrophy, axial 
hypotonia, facial dysmorphy, posterior embryotoxon, and hepatomegaly. Abnormal findings 
of metabolic screening tests included hyperbilirubinemia, hypoketotic dicarboxylic aciduria, 
increased C26:0 and decreased C22:0 plasma levels, and strongly reduced plasmalogen 
concentrations. In fibroblasts, both peroxisomal α- and β-oxidation were impaired. Liver 
histology revealed bile duct paucity, cholestasis, arterial hyperplasia, very small branches of 
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the vena portae, and parenchymatic destruction. Immunocytochemical analysis of cultured 
fibroblasts demonstrated that the cells contain peroxisomal remnants lacking apparent matrix 
protein content and Pex14p, a central membrane component of the peroxisomal matrix protein 
import machinery. Transfection of fibroblasts with a plasmid coding for wild-type Pex14p 
restored peroxisomal matrix protein import indicating that the primary genetic defect 
affecting the patient is indeed linked to PEX14. Mutational analysis of this gene revealed a 
genomic deletion leading to the deletion of exon 3 from the coding DNA (c.85-?_170+?del) 
and a concomitant change of the reading frame (p.[Ile29_Lys56del;Gly57GlyfsX2]). 
CONCLUSIONS: This report represents the second PEX14-deficiency associated with 
Zellweger syndrome and the first documentation of a Pex14p-deficient patient with detailed 
clinical follow-up and biochemical, morphological, and radiological data. 
 
 
2. INTRODUCTION 
Human peroxisomes harbor a number of essential metabolic functions including ether 
phospholipid biosynthesis, fatty acid β-oxidation, fatty acid α-oxidation, and glyoxylate 
detoxification [1,2]. Loss of one or several of these functions leads to a wide variety of 
genetically heterogeneous metabolic disorders which are usually subdivided into two groups: 
the single peroxisomal enzyme deficiencies, and the peroxisome biogenesis disorders 
(PBDs) [2-4]. Until now, 10 single peroxisomal enzyme deficiencies have been identified [2]. 
In addition, 13 genes (termed PEX genes) known to be associated with PBDs have been (at 
least partially) molecularly characterized [3,4]: PEX5 and PEX7 encode the cycling signal 
recognition factors for newly synthesized peroxisomal matrix proteins containing a 
C-terminal (PTS1) and N-terminal (PTS2) peroxisome targeting signal, respectively; PEX13 
and PEX14 encode the peroxisomal membrane proteins (PMPs) constituting the PTS-receptor 
docking complex; PEX2, PEX10, and PEX12 encode PMPs acting downstream of the 
PTS-receptor docking event; PEX1, PEX6, and PEX26 encode peroxins involved in the 
release of Pex5p from the peroxisomal membrane to the cytosol; and PEX3, PEX16, and 
PEX19 encode key players in PMP-biogenesis. 
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The severe and often fatal cerebro-hepato-renal syndrome of Zellweger (ZS; MIM #214100) 
can be considered as the archetypical PBD (MIM #601539) [5]. Patients suffering from this 
disease clinically manifest craniofacial abnormalities, severe hypotonia, psychomotor 
retardation, hepatomegaly with prolonged jaundice, liver dysfunctions, renal cysts, bone 
stippling of multiple joints, and neuronal migration defects [3,4]. Biochemically these patients 
are usually characterized by elevated very long chain fatty acid (VLCFA) and low 
plasmalogen levels [4]. Mutations in PEX1 are the genetic cause of PBDs in approximately 
70% of all patients [4]. Here we report the identification of a novel PEX14 mutation. Until 
now, only one patient with a PEX14 deficiency (c.553C>T; p.Q185X; MIM #601791) has 
been documented [6]. 
 
Pex14p was initially identified as a peroxisomal docking factor for the PTS1-receptor 
Pex5p [7-9]. More recently, it was proposed that Pex14p is also the site from which Pex5p 
leaves the peroxisomal compartment [10]. The PEX14 gene has been assigned to chromosome 
1p36.22 [11], and in silico mapping of PEX14 by alignment of the reference sequence 
NM_004565 to the UCSC chromosome 1 draft sequence displayed a gene extending over a 
large genomic area (approximately 155.8 kb) consisting of nine different exons [12]. 
 
 
3. MATERIALS AND METHODS 
3.1. Patient samples 
The patient’s parents signed a written informed consent form, approved by the institution’s 
Ethical Committee. A percutaneous liver biopsy and a skin punch biopsy were taken from the 
patient. Control skin fibroblasts were kindly provided by Dr. G. Matthys (CME, K.U.Leuven, 
Belgium). For electron microscopy, small fragments of the liver biopsy were immediately 
fixed in 2.5% (v/v) glutaraldehyde (in 0.1 M phosphate buffer) at 4°C overnight. After 1 h of 
post-fixation in 1% (w/v) osmium tetroxide (in 0.1 M phosphate buffer) at 4°C, the samples 
were dehydrated in graded series of alcohol and embedded in epoxy resin. Ultra-thin sections 
of 50 to 60 nm were cut, stained with uranyl acetate and lead citrate and examined at 50 kV 
using a Zeiss EM 900 electron microscope. Images were recorded digitally with a Jenoptik 
Progress C14 camera system operated by using Image-Pro express software. 
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3.2. Fibroblast studies 
Degradation and esterification of fatty acids by cultured fibroblasts were measured essentially 
as described before [13,14]. For transfections and (immuno)fluorescence microscopy, the 
cells were cultured and processed as described elsewhere [15,16]. Fluorescence was 
monitored with a CellM imaging station (Olympus) equipped with U-MNUA2, U-MNIBA3, 
and U-MWIY2 fluorescence mirror units. 
 
3.3. Antibodies 
To raise a mouse polyclonal antiserum against catalase, the bovine protein (Boehringer) was 
purified by size exclusion chromatography using a Superdex HiLoad 16/60 column (GE 
Healthcare Life Sciences). Next, the purified protein was emulsified with an equal amount of 
Freund’s complete adjuvant (priming dose) or Freund’s incomplete adjuvant (successive 
boosting doses) and injected into the peritoneal cavity of a mouse (injection volume: 0.2 ml; 
catalase concentration: 500 µg/ml). Animal care approval was granted by the local 
institutional Ethics Committee. The rabbit antibodies against HsPex13p, HsPex14p, and 
peroxisomal thiolase are described elsewhere [15,17]. The rabbit anti-PMP70 and 
anti-glutamate dehydrogenase (GDH) antisera were from Zymed Laboratories and Rockland, 
respectively. All secondary antibodies were from Sigma. 
 
3.4. Plasmids and strains 
The oligonucleotides (Eurogentec) synthesized for this study are compiled in supplementary 
Table S1 p.117. The bicistronic expression plasmid coding for EGFP-PTS1 and non-tagged 
Pex14p was constructed by exchanging the EGFP-cassette in pIRES2-EGFP (Clontech) for 
EGFP-PTS1 (primers: pIRES2-EGFPfw, pIRES2-EGFP-KSKL), and inserting the cDNA 
coding for non-tagged Pex14p (template: pMF120 [15]; primers: HsPex14.2, HsPex14.3) into 
the multiple cloning site. The plasmid pKG122 has been described elsewhere [18]. 
 
3.5. RNA isolation and RT-PCR 
The RNAqueous-4PCR Kit (Ambion) was used to isolate total RNA from patient and control 
fibroblasts. The HsPEX14 mRNA was copied into its complementary DNA sequence by 
employing the RETROscript Kit (Ambion) in combination with oligo(dT) primers. 
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Subsequently, the PEX14 open reading frame was amplified by PCR using Pfx DNA 
polymerase (Invitrogen) and four pairs of PEX14-specific primers. The corresponding PCR 
products were cloned yielding the following plasmids: pSH17, a pEGFP-C1-derivative 
encoding full-length Pex14p (primer pair: HsPex14.1, HsPex14.rvSalI); pSH18, a pEGFP-C1-
derivative encoding Pex14p(1-200) (primer pair: HsPex14.fwSalI, HsPex14.rv1); pSH19, a 
pGAD424-derivative encoding Pex14p(138-377) (primer pair: HsPex14.fw1, HsPex14.2); and 
pSH20, a pGEX-4T-3-derivative encoding full-length Pex14p (primer pair: HsPex14.fwSalI, 
HsPex14.rvNotI). The cDNA inserts were analyzed by DNA sequencing (Agowa). 
 
3.6. Mutation analysis of genomic DNA 
The high Pure PCR Template Preparation Kit (Roche) was used to isolate genomic DNA from 
cultured fibroblasts. A nested-PCR strategy was used to map the mutation in the PEX14 gene 
(see supplementary Table S2 p.118). PCR products were analyzed using standard agarose gel 
electrophoresis. The secondary structure outputs of the single-stranded genomic DNA 
breakpoint region were generated by the Mfold web server [19; 
http://frontend.bioinfo.rpi.edu/applications/mfold/]. 
 
3.7. Other methods 
Bilirubin, transaminases, alkaline phosphatases, blood counts, chemistry and viral serology 
were performed at the central clinical lab of the Leuven University Hospital, using standard 
techniques. Plasma and urine amino acids were analyzed on a Biochrom 20-plus amino acid 
analyzer (Biochrom Ltd) using cation-exchange chromatography with lithium citrate-based 
buffers. VLCFAs, pristanic acid, and phytanic acid were measured by capillary GC/MS after 
methylation. Urinary organic acids were measured by GC/MS in selected ion mode after 
acidic extraction and derivatization with N,O-bis(trimethylsilyl)trifluoroacetamide containing 
1% of trimethylchlorosilane. Plasmalogen content of lipid extracts of red blood cells was 
deduced from GC-analysis of the fatty acid methyl esters or by quantifying the acid-released 
fatty aldehydes as p-nitro-phenylhydrazones by RP-HPLC [20]. For karyotyping, cultured 
white blood cells were treated with 10 µg/ml colcemid for 120 or 240 min before 
trypsinization, treated hypotonically (0.75 M KCl) at 37°C and fixed with 3:1 methanol:acetic 
acid. G-banded metaphases were analyzed and karyotyped. 
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4. RESULTS 
4.1. Case history 
The boy was born after 36 weeks of pregnancy to related, Pakistani parents. Pregnancy was 
established by in vitro fertilization and was uneventful except for a moderate third trimester 
vaginal blood loss. Birth weight, length, and head circumference were 2120 g (<p3), 48 cm 
(p3) and 35 cm (<p3), respectively. The mother has a mentally retarded sib (no further details 
available) and her sister had 3 children (also from a consanguineous marriage), who all died 
(one girl in the first postnatal days, one boy at the age of 3-4 months, and one boy at the age 
of 10 months with icterus and intracerebral hemorrhage). The patient showed prolonged 
neonatal hyperbilirubinemia responding to phototherapy. At three months of age, the patient 
presented with icterus, dystrophy, facial dysmorphy (slight dolichocephaly, triangular face, 
and large normotonic fontanel) (Figure 6.1.A), striking axial hypotonia, and hepatomegaly 
(5 cm below the costal margin). His gaze fixed and followed normally, he had normal 
spontaneous movements in all limbs but deep tendon reflexes were absent. Biochemical 
testing showed hyperbilirubinemia (total/direct bilirubin: 5.35/3.73 mg/dl; normal: 
0.2-1.0/≤0.5 mg/dl) without evidence for hemolysis. Serum alkaline phosphatase was slightly 
increased (1466 U/l; normal: <1107 U/l) and transaminases were about 5 times the upper limit 
of normal (ULN). Blood count, routine chemistry and karyotype were normal, and serology 
for hepatotropic viruses was negative. Metabolic screening at this age showed (i) normal 
plasma amino acids, phytanic acid, pristanic acid, and C24:0 levels, (ii) increased C26:0 
(11.45 µM; normal: 0.30-1.30 µM) values, and (iii) decreased C22:0 (17.0 µM; normal: 
28.0-96.0 µM) and plasmalogen concentrations. The plasmalogen levels were measured as the 
ratio of C16:0 dimethylacetal (DMA) to C16:0 (0.02; normal: 0.065-0.095) and the ratio of 
C18:0 DMA to C18:0 (0.00; normal: 0.180-0.220). Urine organic acid analysis showed 
hypoketotic dicarboxylic aciduria, without glycine conjugates but with increased 
concentrations of adipic acid (>1.5 x ULN), suberic acid (>39 x ULN), sebacic acid 
(>109 x ULN), 4-OH-phenyllactic acid (>9 x ULN), 3-OH-sebacic acid (>6 x ULN), 
3-OH-suberic acid (>5 x ULN), 5-OH-hexanoic acid (>2 x ULN), and 7-OH-octanoic acid 
(>82 x ULN). Radiological examination of the skeleton was normal. Ophtalmological 
examination showed posterior embryotoxon. Cerebral ultrasound and electroencephalography 
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were normal. Histological examination of a liver biopsy showed paucity of intrahepatic bile 
ducts as well as arterial hyperplasia and very small branches of the vena portae. Electron 
microscopy analysis of the liver revealed severe parenchymatic destruction and cholestasis 
(Figure 6.1.B), and only abnormal small bodies resembling incompletely developed 
peroxisomes could be found (Figure 6.1.C)7
                                               
7 The peroxisomal nature of these aberrant organelles is corroborated by the fact that these structures correspond 
to the electron-dense core organelles which were previously identified as peroxisomal ghosts in liver cells of 
PBD patients (see [130] in general reference list). 
. Rare areas with filamentous material were seen 
in the hyaloplasm of the hepatocytes (Figure 6.1.D). Percutaneous cholangiography was 
normal. The patient was treated with fat-soluble vitamin supplements, ursodeoxycholic acid 
(5-10 mg/kg) and prokinetics, and received Heparon as formula, initially through nasogastric 
tube feeding. Brain MRI at 5 months and CT at 13 months showed a polymicrogyria-type of 
cortical developmental abnormality in the right frontal and parietal cortex and left Rolandic 
cortex (Figure 6.1.E), and bilateral zones of laminar heterotopia (Figure 6.1.F). Cerebellum 
and brain stem were normal. At the age of 21 months, the patient’s weight was 9.3 kg (<p3), 
length 78 cm (p3) and head circumference 48 cm (p10-25). He had lost vision (from 
16 months on), showed generalized hypotonia and had no spontaneous movements anymore. 
He was still mainly drinking formula, and only occasionally eating fruit or vegetable mash 
(pristanic/phytanic low diet). He responded to pain and occasionally demonstrated a social 
smile. Biochemically, the cholestasis had completely disappeared (normal bilirubin and 
alkaline phosphatase) but transaminases had remained high (5-10 x ULN). Plasma phytanic 
acid was at the upper limit of normal (8.61 µM; normal: 0.37-8.62 µM) and pristanic acid 
increased (7.7 µM; normal: 0-4 µM) from the age of 14 months on. Plasmalogen content of 
erythrocytes was still low (C16:0 DMA/C16:0 = 0.011; C18:0 DMA/C18:0 = 0.031; 
plasmalogen/total phospholipids = 0.025). The patient was admitted to the hospital on two 
separate occasions since his diagnosis, once for suspected epileptic seizure (unresponsiveness, 
cyanosis) at 13 months, and once for pneumonia at 18 months. Currently, he is being taken 
care of by the parents at home. 
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Figure 6.1. Facial profile, liver ultrastructure, and MRI brain scan of the patient 
(A) Lateral view of the patient’s head at the age of 20 months, showing slight megalocephaly and low implanted 
ears. Parental informed consent was obtained for publication of this figure. (B) Electron microscopy of the liver 
showed severe parenchymatic destruction and cholestasis (dilated cholestatic bile canaliculi: arrows). (C) In the 
cytoplasm of most hepatocytes, peroxisomes were absent; only abnormal small bodies resembling incompletely 
developed peroxisomes or peroxisomal ghosts (arrow) could be observed. (D) Rare areas with fibrillar material 
(arrow) were seen in the hyaloplasm of some hepatocytes. (E) Polymicrogyria is seen in the right frontal and 
parietal cortex and in the left Rolandic cortex (arrows). (F) Bilateral symmetrical laminar heterotopia is seen as a 
thin line of grey matter between the ventricle and the cortex in the frontal and parietal lobe (arrows). 
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4.2. Analysis of peroxisomal functions in fibroblasts 
As the clinical phenotype, the biochemical testing and the liver ultrastructure of the patient 
were compatible with Zellweger syndrome, cultured skin fibroblasts were used to study 
peroxisome function and biogenesis. Functional measurements demonstrated impaired 
α-oxidation, defective β-oxidation of both 2-methyl branched long chain fatty acids and 
VLCFAs (Table 1), and a plasmalogen deficiency (data not shown). Immunofluorescence 
microscopy analysis revealed the absence of catalase- and thiolase-positive particles 
(Figure 6.2.A-B). On the other hand, the cells contained PMP70-and Pex13p-positive 
vesicular membrane structures, the so-called ‘ghosts’, which appear somewhat larger in size 
and less abundant than normal peroxisomes (Figure 6.2.A). Interestingly, incubation of the 
cells with an antibody against the peroxisomal membrane protein Pex14p yielded negative 
staining results indicating that this PMP was absent (Figure 6.2.A), which was confirmed by 
immunoblot analysis of total lysates from liver and skin fibroblasts (Figure 6.3.). In addition, 
expression of wild-type Pex14p in these fibroblasts restored peroxisomal matrix protein 
import in virtually all transfected cells (Figure 6.2.C), while transfection with all other known 
human cDNAs encoding PEX proteins did not (data not shown). 
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Table 1. Biochemical measurements in cultured skin fibroblasts 
Oxidation (in nmol/24 h/mg protein) represents the sum of both labeled CO2 and acid soluble metabolites formed 
during 20-24 hour incubations with 4 µM [1-14C]-labeled fatty acids or CO2 plus formate for 
3-methylhexadecanoic acid; esterification (in nmol/24 h/mg protein) represents the label recovered in 
triglycerides and phospholipids. For the patient, values obtained from two separate incubations are given. For the 
controls, the number of separate incubations is given between brackets. As reported before [13], uptake of fatty 
acids by monolayers is not linearly related to the number of cells (confluency), hence the ratio 
oxidation/esterification (O/E) is more accurate to document deficiencies. N.M., not measurable; S.E., standard 
error of the mean. 
 
 
  patient  mean ± S.E. for controls 
parameter substrate oxidation esterification O/E  oxidation O/E 
mitochondrial 
β-oxidation 
[1-14C]palmitic 
acid 
3.52 
2.98 
19.10 
18.20 
0.185 
0.164 
 2.64 ± 0.49 
(12) 
0.123 ± 0.024 
(8) 
peroxisomal 
β-oxidation 
2-methyl-[1-14C]-
hexadecanoic acid 
0.291 
0.151 
9.28 
12.00 
0.031 
0.013 
 23.4 ± 2.36 
(14) 
2.43 ± 0.32  
(4) 
 [1-14C]-lignoceric 
acid 
0.141 
0.126 
1.24 
1.26 
0.113 
0.101 
 0.603 ± 0.202 
(6) 
0.305 ± 0.046 
(5) 
peroxisomal 
α-oxidation 
3-methyl-[1-14C]-
hexadecanoic acid 
N.M. 
0.035 
15.90 
12.80 
0.000 
0.003 
 2.40 ± 0.31 
(15) 
0.081 ± 0.015 
(4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. (next page) Immunocytochemical localization of peroxisomal proteins in patient and control 
fibroblasts 
(A) Control (CT) and patient (ZS) fibroblasts were processed for immunostaining with antibodies specific for 
catalase, Pex13p, PMP70, or Pex14p (red). (B) As we experienced difficulty detecting endogenous thiolase in 
human skin fibroblasts, the cells were transfected with a plasmid coding for rat thiolase B (rthiolase) two days 
prior to immunostaining with anti-thiolase B antibodies. (C) Cultured patient fibroblasts were (co)transfected 
with pMF1220, a bicistronic plasmid encoding non-tagged human Pex14p and EGFP-PTS1, or pGK448 and 
pKG122, two monocistronic plasmids encoding non-tagged human Pex14p and rat thiolase B, respectively. After 
two days, the cells were processed for fluorescence microscopy using rabbit anti-Pex14p antibodies  (upper row) 
or rabbit anti-thiolase B (red) and mouse anti-catalase (green) antibodies (lower row). Note that catalase and 
EGFP-PTS1, two PTS1-containing proteins, as well as thiolase B, a PTS2-containing protein, display a punctate 
staining pattern indicating the reconstitution of functional peroxisomes. The nuclei were counterstained with 
DAPI (blue), and transfected cells are marked by arrows. Scale bars represent 20 µm. 
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Figure 6.3. Immunoblot analysis of Pex14p in patient and control fibroblasts 
Equal amounts of total protein extracted from cultured skin fibroblasts (two left panels) or liver (two right 
panels) from a control (CT) or the Zellweger (ZS) patient were subjected to SDS-PAGE and transferred to 
nitrocellulose. The membranes were then probed with antisera raised against Pex14p and GDH (loading control). 
The migration of relevant molecular mass markers (expressed in kDa) is indicated. 
 
 
4.3. Mutational analysis of PEX14 
In order to identify the causative genetic defect in the patient, the coding sequence of PEX14 
was amplified by RT-PCR using four distinct primer sets. Cloning and sequence analysis of 
the amplified sequences revealed that all cDNA fragments covering the 5’-end of the PEX14 
mRNA transcript were lacking exon 3 (c.85_169del85) (Figure 6.4.). In the deduced protein 
sequence, the deletion of exon 3 (p.Ile29_Lys56del) causes a frameshift leading to a 
premature stop codon immediately downstream of exon 2 (p.Gly57GlyfsX2) (Figure 6.4.). To 
identify the underlying mutation at the genomic level, we used a nested-PCR strategy 
(supplementary Table S2 p.118 and Figure 6.5.). By employing this approach, we detected a 
deletion of approximately 41 kilobase pairs containing exon 3 (Figure 6.5.B-C). 
Unfortunately, as we were not able to amplify a genomic PCR fragment spanning the putative 
breakpoint region, the precise breakpoint positions could not be identified. In this context, it 
should be noted that Mfold predictions for the single-stranded genomic DNA 3’-breakpoint 
region (see Figure 6.5.B, sample series 4) pointed towards the presence of two strong 
stem-loop structures in the region covered by the PCR reactions 4b, 4c, and 4d (folding 
parameters: temperature = 68°C; [Na+] = 100 mM; [Mg2+] = 1.3 mM; data not shown). Also, 
as DNA samples from the parents were not available for further studies, we were unable to 
confirm that the same deletion was found in both parents in a heterozygous state. 
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Figure 6.4. Automated sequence chromatogram of the 5’- and 3’-flanking region of exon 3 from control 
and patient cDNA 
The deduced amino acids (one-letter code) are presented below the nucleotide sequences. The subscript numbers 
refer to the position of the amino acid in the wild-type protein. Note that a deletion of exon 3 in the patient’s 
cDNA results in a reading frame shift leading to a premature stop codon (*) in exon 4. 
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Figure 6.5. Mutation analysis of the PEX14 gene 
(A) Genomic organization of the human PEX14 gene with schematic representations of the exon-intron 
structures (adapted from [12]). Black boxes represent the coding regions, and grey boxes represent the 5’- and 
3’-untranslated regions (UTRs) of the gene. The intron sizes are indicated in kilobase pairs. (B) Schematic 
representation of the nested-PCR strategy. Each circled number represents a nested-PCR reaction carried out 
with the primer pair combinations listed in supplementary Table S2 p.118: black characters on a white 
background indicate that a specific PCR product was obtained from both the control and the Zellweger patient’s 
genomic DNA; white characters on a black background indicate that a specific PCR product could only be 
obtained from the control patient’s genomic DNA; and black characters on a grey background indicate that no 
specific PCR product could be obtained. (C) DNA fragment analysis of the nested-PCR reactions listed in 
panel B (+, control; -, patient). The numbers under each lane refer to the expected size (in bp) of each PCR 
product. The molecular mass markers (in bp) are also indicated. 
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5. DISCUSSION 
Pex14p functions as a central component of the peroxisomal matrix protein import 
machinery [10]. So far, only one PEX14 mutation in exon 6 (c.553C>T; p.Q185X) has been 
characterized in Zellweger spectrum patients [6]. The previously described patient died at 
10 days of age, and clinical, morphological or radiological data were not reported [6]. Here 
we report the identification and clinical presentation of a second Zellweger patient with 
Pex14p-deficiency. The first reported Pex14p-deficient Zellweger patient was of Japanese 
origin, our patient was born to Pakistani parents. The diagnosis in both reported cases was 
based on clinical characteristics, increased very long chain fatty acids and low plasmalogen 
levels. In the first reported case, phytanic acid was normal. In our case, phytanic and pristanic 
acid remained normal until 14 months of age. Liver ultrastructure confirmed the absence of 
normal peroxisomes, brain MRI showed polymicrogyria and laminar heterotopia. At this 
moment, therapy for patients suffering from PBDs is mainly supportive. In addition, 
therapeutic interventions mostly target individual biochemical defects, and their effects on 
clinical outcome have not yet been proven [4]. The patient we describe was treated with oral 
administration of bile acids and a phytanic/pristanic acid-low diet. Bile acid supplements have 
been reported to improve hepatobiliary function in infants with Zellweger syndrome [21,22]. 
In our patient, normalization of cholestasis was achieved and hepatomegaly regressed, but 
neurological function deteriorated significantly during follow-up. 
 
Mutation analysis of the PEX14 gene revealed a homozygous deletion causing an out-frame 
skipping of exon 3 in the mRNA transcript. The peptide encoded by exon 3, corresponding to 
the amino acid residues 29 to 56 of the full-length protein, is located in the most conserved 
region of Pex14p [10]. This region is known to be essential for binding to Pex5p, Pex13p, and 
Pex19p [23-27] and has also been shown to be part of the topogenic sequence [26,27]. Note 
also that two Pex14p-deficient Chinese hamster ovary cell lines have been identified [28,29]. 
In these cells, the PEX14 mRNA transcripts contained frameshift deletions of the exons 2 
and 4, respectively [8,28]. In addition, it has been shown that the minimal functional region of 
Pex14p required for restoring impaired matrix protein import in these cell mutants lies 
between amino acid residues 21 and 260 [27]. In our patient, the deletion of exon 3 led to a 
deficiency of Pex14p and the absence of normal peroxisomes from cultured skin fibroblasts, 
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supporting the data mentioned above. These abnormalities could be entirely reversed by 
transfection of wild-type PEX14 in the fibroblasts. We therefore consider it proven that the 
described mutation is causative of the PBD and the described clinical picture. 
 
The fact that the first reported patient died at 10 days of age, while our patient is currently 
surviving beyond 21 months, with both patients demonstrating a total absence of functional 
Pex14p, is difficult to explain. The exact cause of death of the first reported patient is not 
documented, but theoretically genetic modifiers, degree of brain malformation or liver failure 
and access to supportive treatment could be invoked to explain the difference in survival. In 
any case, the fact that the clinical picture is not necessarily as severe as first reported is 
noteworthy, although variability of the clinical picture and survival are not surprising in 
Zellweger spectrum patients. 
 
In conclusion, we report that a novel deletional frameshift mutation in exon 3 of PEX14 is 
associated with Zellweger syndrome, comprising severe but regressing cholestasis and 
hepatomegaly, radiological indications of a neuronal migration defect and cortical 
developmental anomaly, and rapidly progressive hypotonia. 
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Supplementary Table S1. Synthetic oligonucleotide primers used in this study (restriction sites are underlined) 
 
Name Nucleotide sequence 
14E23fw1 5’-CAAGCCACATCTACTCTAC-3’ 
14E23fw2 5’-CTGTAATCCTACTTTGAA-3’ 
14E23fw7 5’-GAGTCAAGAGTAACTGAAG-3’ 
14E23fw8 5’-CATATGTTCACACTTACATG-3’ 
14E23fw15 5’-GTCCAGAACTGGTCTATTAC-3’ 
14E23fw16 5’-GTCCGATGGATCCGTTTTG-3’ 
14E23fw17 5’-GCACTGCATTGAGTGCACC-3’ 
14E23rv1 5’-GCTTTAAGACTAATAGAC-3’ 
14E23rv2 5’-CCCACAAGTGGTTCAGCATCC-3’ 
14E23rv9 5’-GTGTACCAGGTGTCAGCGG-3’ 
14E23rv10 5’-CAGAAGATGCTAGTAGTACAG-3’ 
14E23rv11 5’-CACGCGAAGTGTGTGTTTACG-3’ 
14E23rv12 5’-GGGGCTGTTTTAAATGACTGC-3’ 
14E34cfw 5’-GACAGAGCCTCACACTGTC-3’ 
14E34dfw 5’-GCGATCTTGGCTCACTGCAAC-3’ 
14E34fw3 5’-GTGTTGTGCTCTGTGACTTC-3’ 
14E34fw4 5’-CTGGGTGAGGGTGAGTAGGG-3’ 
14E34fw9 5’-GACAGAGTGAGATTCCAACTC-3’ 
14E34fw10 5’-GTCCCATCAACAGAAAAGTGG-3’ 
14E34fw20 5’-CTTTCAGGGATATCTATTCTG-3’ 
14E34fw21 5’-CTTCCCAGGTTCAAGTGATTC-3’ 
14E34fw22 5’-GACCTCAGGTGGTCCACC-3’ 
14E34fw23 5’-GGATTACAGGCGTGAGCC-3’ 
14E34fw24 5’-GCACTCCAGCCTGGGTGAC-3’ 
14E34fw25 5’-GAGAGTTCTTGGCTTTCAGTC-3’ 
14E34fw26 5’-GAAGGTACTGGAGAGCCAC-3’ 
14E34fw27 5’-GCAAGCAGAAATTGGAGTG-3’ 
14E34fw28 5’-CTGTCTCAATATGCTACTTGAG-3’ 
14E34fw29 5’-GCATCTGTTTGATTAGTAACAG-3’ 
14E34gfw 5’-GTGTGGGACAGCTAGAGCTCTTC-3’ 
14E34hfw 5’-CTCTGCTGGTGGGAGTGTG-3’ 
14E34brv 5’-TGGGGGGTAGGGTCAGTCCTGC-3’ 
14E34drv 5’-CTCCTTTTGTTCAACATTATGC-3’ 
14E34rv3 5’-GATATGATGCCTGCCTGGCAAG-3’ 
14E34rv4 5’-CTGCTTCTATATATAGACTGG-3’ 
14E34rv13 5’-GCCATATGGTCAGAGAAGCAG-3’ 
14E34rv14 5’-TAAATGTACCATGGGTGTTG-3’ 
14E34rv20 5’-AGGGTCACAGGGTCCTG-3’ 
14E34rv21 5’-GTAGAGGCTCTGGATTCTG-3’ 
14E34rv24 5’-GCATGTGCCACCAAGCCCAG-3’ 
14E34rv25 5’-CTGTTATCCACCTGCCTCTGC-3’ 
14E34rv26 5’-CACTGGTTCAGTGTTTATGGAC-3’ 
14E34rv27 5’-CTCTTTCCTTAGTTTCTTTCTC-3’ 
14E34rv30 5’-GCATGGTGGCAGGTACCTG-3’ 
14E34rv31 5’-CTACTCAGGAGGCTGAGGC-3’ 
14exon2.fw1 5’-CTCTTTGGGCTACTTTTTAC-3’ 
14exon2.fw2 5’-GGTAGTCCACTGCAAAATAC-3’ 
14exon2.rv1 5’-CTCACTCGTCCCCACACGC-3’ 
14exon2.rv2 5’-CGAGAAGAGAAGTCAGAGGTC-3’ 
14exon3.fw1 5’-CAGGGAAACAACATCGCCTTTC-3’ 
14exon3.fw2 5’-GGTAGATCT
14exon3.rv1 
TAAGTTTAAGAAATAACTG-3’ 
5’-CCATTGTCAGGAAAGAAAC-3’ 
14exon3.rv2 5’-AACCTGCAG
14exon4.fw1 
GCCCCACTGGGGGGTTCG-3’ 
5’-CTGTCGCTTAAGGTTAAATTG-3’ 
14exon4.fw2 5’-GCAACTGAGAGAGGTTCCG-3’ 
14exon4.rv1 5’-CTTTAAAAAGTTTGTCTAGAAG-3’ 
14exon4.rv2 5’-GAAGACTGGGGTGTGTCAC-3’ 
HsPex14.1 5’-GGAAAGATC
HsPex14.2 
TTGATGGCGTCCTCGGAGCAG-3’ 
5’-AAACTGCAG
HsPex14.3 
CTACCTGGGCTCCAAGCTG-3’ 
5’-GGGAAGATCT
HsPex14.fw1 
ATGGCGTCCTCGGAGCAG-3’ 
5’-GGGAATTC
HsPex14.fwSalI 
GGCCGAGAGGACAGAAAGC-3’ 
5’-AGGAGTCGACATGGCGTCCTCGGAGCAGGC-3’ 
HsPex14.rv1 5’-GGCTGCAG
HsPex14.rvNotI 
GGTGGATGTGGTGGCCTTG-3’ 
5’-ACCGCCGCGGCCGC
HsPex14.rvSalI 
CTAGTCCCGCTCACTCTC-3’ 
5’-GGGGGTCGAC
pIRES2-EGFPfw 
CTAGTCCCGCTCACTCTC-3’ 
5’-GGCGGTAGGCGTGTAC-3’ 
pIRES2-EGFP-KSKL 5’-GCGCGCGCGGCCGCTCACAGCTTGGACTTCTTGTACAGCTCGTCCATGC-3’ 
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Supplementary Table S2. PCR reactions carried out on human genomic DNA 
condition primers (first reaction) primers (nested reaction) fragment length 
1a 14exon2.fw1/14exon2.rv1 14exon2.fw2/14exon2.rv2 366 
1b 14exon3.fw1/14exon3.rv1 14exon3.fw2/14exon3.rv2 395 
1c 14exon4.fw1/14exon4.rv1 14exon4.fw2/14exon4.rv2 450 
2a 14E23fw1/14E23rv1 14E23fw2/14E23rv2 401 
2b 14E23fw7/14E23rv9 14E23fw8/14E23rv10 983 
2c 14E34fw3/14E34rv3 14E34fw4/14E34rv4 420 
2d 14E34fw9/14E34rv13 14E34fw10/14E34rv14 1327 
2e 14E34gfw/14E34drv 14E34hfw/14E34drv 267 
3a 14E23fw16/14E23rv9 14E23fw17/14E23rv10 216 
3b 14E23fw15/14E23rv11 14E23fw15/14E23rv12 552 
3c 14E34cfw/14E34brv 14E34dfw/14E34brv 359 
3d 14E34fw26/14E34rv20 14E34fw27/14E34rv21 600 
4a 14E34fw28/14E34rv26 14E34fw29/14E34rv27 454 
4b 14E34fw20/14E34rv24 14E34fw21/14E34rv25 348 
4c 14E34fw24/14E34rv30 14E34fw25/14E34rv31 294 
4d 14E34fw22/14E34rv20 14E34fw23/14E34rv21 1498 
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During this research project, we endeavored to establish a mammalian model system suitable 
to study peroxisome degradation and the initial stages of peroxisome biogenesis. A better 
understanding of these biological processes is essential to unravel the still puzzling aspects of 
the peroxisomal life cycle. 
 
In our first approach, we used the Flp-In T-REx system (Invitrogen) which allows tetracycline 
inducible expression of a gene of interest at a specific genomic location. A Flp-In T-REx cell 
line expressing a dominant-negative variant of HsPex3p in a regulable manner would be an 
attractive tool to manipulate peroxisome abundance. However, several attempts to generate 
such a cell line were not successful. Notwithstanding a clear dominant-negative effect of 
HsPex3p(1-44) could be observed in transient expression experiments, the expression levels of 
the HsPex3p variant were insufficiently high to result in a dominant-negative phenotype in 
the stable cell line. In this context, it is interesting to point out that some of our later findings 
revealed that Pex3p is a short-lived protein. Therefore, we speculate that – albeit the Tet Off 
system has already been successfully used to generate a cell line with tetracycline-regulated 
autophagy [131] – the turnover of HsPex3p(1-44) is too fast to reach expression levels 
sufficiently high to influence peroxisome abundance. 
 
The second strategy for the generation of our cell model was based on the HaloTag 
Interchangeable Labeling technology (Promega). Over the past decade, various technologies 
for the selective chemical labeling of proteins in living cells have been developed. Fusion of a 
self-labeling protein tag to the protein of interest provides a means for either noncovalent or 
covalent attachment of small molecular probes (e.g. fluorophores) to the protein under 
study [132]. Important advantages of chemical labeling procedures over the use of 
autofluorescent proteins (e.g. EGFP) include (i) the possibility to use different dyes in 
combination with one single genetic construct, and (ii) the ability to perform pulse-chase 
experiments. Currently, a variety of self-labeling fusion tags is used for intracellular imaging 
in living cells (e.g. tetracysteine tag, Snap tag, CLIP tag) [132]. In our research, we have used 
the HaloTag, a protein tag of 33 kDa derived from the haloalkane dehalogenase enzyme of 
Rhodococcus rhodochrous. The HaloTag reporter protein is a catalytically inactive derivative 
of the dehalogenase and is designed to covalently bind to synthetic ligands comprising a 
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common chloroalkane reactive linker [133]. These linkers can be attached to a variety of 
functional reporters such as fluorescent dyes (e.g. TMR), affinity handles (e.g. biotin), or solid 
surfaces (e.g. a resin consisting of Sepharose beads). Covalent bond formation between the 
protein tag and the chloroalkane linker is highly specific, occurs rapidly under physiological 
conditions, and is essentially irreversible. The stability of the bond permits live cell imaging 
during a long time period and makes the technique compatible with fixation procedures. 
 
By using the HaloTag technology, we could establish a simple tool to study peroxisome 
dynamics in cultured mammalian cells (see Chapter IV). A possible model, incorporating our 
results, is presented in Figure 7.1. In summary, we showed that 80 to 90 percent of all 
peroxisomes are protein import-competent, and suggest that these organelles generally 
multiply by growth and non-symmetrical fission events. We also demonstrated that the 
half-life of the peroxisomal matrix reporter protein is approximately two days, and that 
macroautophagy is the preferred mechanism for degrading (dysfunctional) peroxisomes under 
basal conditions. Moreover, we provided evidence that the turnover rate of the investigated 
PMPs is much higher than that of the matrix reporter protein, and that the half-life of these 
PMPs can be extended by inhibiting the proteasome degradation pathway. Finally, as 
peroxisomes do not exchange their protein content, we postulate that the non-symmetrical 
division process may act as a quality control mechanism in which dysfunctional peroxisomal 
proteins are retained within the mother organelle, which – after a limited number of fission 
events – is targeted for macroautophagic degradation. 
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Figure 7.1. Revised model for peroxisome dynamics in mammalian cells 
Peroxisomal proteins are synthesized on free polyribosomes in the cytoplasm and recruited to pre-existing 
protein import-competent peroxisomes (indicated in green) which multiply by growth and division. Upon fission, 
the matrix protein content is evenly or unevenly distributed over the daughter organelles. Excess or 
non-functional PMPs (marked in blue) are continuously removed from the membrane by a 
proteasome-dependent protein degradation pathway. Unnecessary or dysfunctional organelles (indicated in red) 
are rapidly eliminated by macroautophagy. 
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To date, two divergent views regarding peroxisome biogenesis are dominating the peroxisome 
field. On the one hand, new peroxisomes are thought to originate de novo from the 
ER [35,42], and on the other hand, these organelles are believed to arise by growth and 
division of pre-existing peroxisomes [4,34]. The fact that there is evidence supporting both 
models makes peroxisome formation a topic of intense debate. In the ER maturation model, a 
pre-peroxisomal template structure – an immature peroxisomal structure that still needs to 
import matrix proteins and a subset of membrane proteins – is suggested to bud off from the 
ER [40]. Others believe that the source of this pre-peroxisome might be a not yet identified 
vesicular structure already present in the cytosol [134]. So far, the significance and the source 
of such a pre-peroxisomal template remain elusive. The combined findings of studies 
performed in yeasts indicate a co-existence of both peroxisome biogenesis pathways in these 
species. That is, peroxisomes multiply by fission in dividing yeast cells, whereas de novo 
peroxisome formation has been put forward as a rescue mechanism occurring when the cells 
lack any peroxisomal structures. In contrast to yeasts, the situation in mammals is not yet 
clear. Although evidence has been provided for the de novo as well as the division pathway, 
their relative contribution to the total number of peroxisomes in wild-type cells remains 
enigmatic. Our findings obtained by using the HaloTag-based cell model show that 
(i) peroxisomes can multiply by non-symmetrical fission events, (ii) pre-existing peroxisomes 
remain membrane and matrix protein import-competent, and (iii) peroxisomes do not 
exchange their protein content. Altogether these findings indicate that it is highly unlikely that 
peroxisomes mainly arise de novo or from a pre-peroxisomal structure. Importantly, we want 
to emphasize that our data do not exclude a possible role for the ER as donor compartment for 
membrane constituents. Interestingly, we observed that a minority of peroxisomes loses its 
protein import competence, a phenomenon that may be part of a quality control mechanism to 
rid the cell of dysfunctional or superfluous peroxisomes. How this process is triggered will be 
an intriguing topic for further research. 
 
The rapid proteasome-dependent turnover of membrane proteins is not a unique feature for 
peroxisomes since it has also been observed for proteins residing in the ER membrane. For 
example, the mammalian ER stearoyl-CoA desaturase, a multispanning ER membrane 
protein, has been shown to be constitutively degraded by the proteasome with a half-life of 
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approximately three hours [135]. The significant disparity in half-life between peroxisomal 
membrane and matrix proteins fits in our hypothesis regarding peroxisomal quality control. 
PMPs are continuously extracted from the lipid bilayer by an unknown dislocation machinery 
and degraded by the proteasome. At a certain moment, they may no longer be inserted into the 
membrane – due to intraperoxisomal or cytosolic stimuli – disabling the organelle to further 
import matrix proteins. Finally, the dysfunctional peroxisome will be targeted for autophagic 
degradation. 
 
A central research question that will guide our future studies is which factors are playing a 
key role in peroxisome degradation in mammals. For this reason, we will employ the HaloTag 
technology to analyze the half-life of peroxisomes under various environmental conditions 
(e.g. in the presence of reactive oxygen species or autophagy-inducing agents). Moreover, we 
will use the system to identify new players in the process of peroxisome degradation, in 
particular components that specifically target peroxisomes for sequestration by 
autophagosomes. Therefore, we will investigate whether or not small interfering RNAs 
(siRNAs) which are designed to downregulate the expression of putative mammalian 
orthologues of yeast pexophagy-related proteins can block the degradation of pulse-labeled 
peroxisomes. We will validate this approach by employing siRNA against LC3, a protein that 
has already been shown to be involved in the degradation of mammalian peroxisomes [124]. 
Candidate target genes that will be knocked-down include PEX3, PEX14, and ATG9. The 
latter encodes an integral membrane protein required for the formation of the initial 
sequestering compartment which has been shown to be essential for the selective degradation 
of peroxisomes in P. pastoris [136]. In H. polymorpha, Pex3p has been reported to block the 
initiation of sequestration of peroxisomes whereas the N-terminal fragment of Pex14p is 
essential to target peroxisomes for pexophagy (see Chapter I section 3.3.2.). Considering the 
unexpected hindrances we experienced regarding the analysis of the turnover rate of 
peroxisomal remnants in Pex14p-deficient cells (see Chapter V), the Pex14p siRNA approach 
provides a nice alternative to analyze the role of this peroxin in peroxisome degradation. In 
addition, the HaloTag-based model system creates the possibility to analyze siRNA libraries 
in order to find new candidates that selectively target peroxisomes for autophagic degradation. 
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Until now, only five proteins (Atg7p, Atg12p, LC3, p62, and Pex14p) have been implicated in 
the autophagic degradation of peroxisomes in mammalian cells (see Chapter I section 3.4.1.). 
In addition, also a non-autophagic pathway, called 15-lipoxygenase-mediated autolysis, has 
been postulated to be involved in peroxisome turnover under non-proliferative conditions (see 
Chapter I section 3.4.3.). However, these latter findings are based on observations made in 
aldehyde-fixed liver tissues, which are hardly comparable to an in vivo situation. Despite 
these apparently conflicting findings, the proposed degradation pathways are not necessarily 
mutually exclusive. That is, the mechanism for peroxisome degradation may be species or cell 
type specific and depend on environmental conditions. 
 
In future experiments, we will also apply the HaloTag technology to further investigate 
peroxisome dynamics on a morphological and molecular level. However, as this system does 
not allow us to perform complementary studies at the biochemical level, we are currently 
developing another cell model which is based on the destabilizing domain (DD) technology. 
This system involves fusion proteins consisting of a DD domain – derived from the human 
FKBP12 protein which is rapidly and constitutively degraded in mammalian cells – and a 
protein of interest [137]. The DD domain transfers its instability to the protein of interest 
resulting in the rapid degradation of the fusion protein by the proteasome. Addition of a 
cell-permeable high-affinity ligand (e.g. Shield-1) protects the DD domain of being targeted 
for degradation conferring stability to the protein of interest. For our purpose, we will stably 
express a DD fusion protein of Pex19p – a predominantly cytosolic peroxin essential for the 
formation of the peroxisomal membrane – in pex19 human fibroblasts. In the absence of 
stabilizing ligand, these cells should completely lack peroxisomal structures, whereas 
exposure of the cells to the ligand should result in functional complementation and hence 
peroxisome formation. 
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Our work regarding peroxisome dynamics reveals the potential existence of a quality control 
mechanism that may be essential to maintain a healthy peroxisome population. In this context, 
it is interesting to note that an inefficient removal of peroxisomes results in the accumulation 
of non-functional organelles which may contribute to cellular ageing and age-related 
pathologies [7]. Moreover, disturbed peroxisomal processes have been implicated in the 
pathogenesis of a wide variety of diseases ranging from mild metabolic defects to the severe 
Zellweger syndrome. Accordingly, gaining a better insight into peroxisome dynamics is an 
essential prerequisite to comprehend the molecular mechanisms underlying the removal of 
peroxisomes during physiological and pathological processes and to further our understanding 
of diseases linked to peroxisomes. 
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SUMMARY 
Peroxisomes are small organelles which fulfill an indispensable role in the cellular 
metabolism of virtually all eukaryotes. Their significance is highlighted by the existence of a 
group of hereditary diseases ranging from the severe peroxisome biogenesis disorders to the 
milder single peroxisomal protein deficiencies. During the past decades, tremendous work has 
been done in order to get more insight into the metabolic activities of peroxisomes and the 
molecular aspects of peroxisome biogenesis. Only recently, there has been a growing interest 
in how peroxisomes are degraded. Despite the considerable amount of data regarding 
pexophagy in yeasts, peroxisome degradation in mammals is rather poorly characterized. This 
is mainly due to the lack of a reliable model system. Therefore, we aspired to develop a 
mammalian cell model allowing us to study peroxisome degradation at the molecular level 
and under basal conditions by employing the HaloTag technology. 
 
During this work, we could successfully generate a cell model. This model – based on an in 
vivo pulse-labeling technique – allows us to perform a profound analysis of distinct 
peroxisome populations within a single cell. By using this system, we could draw some 
interesting conclusions with respect to peroxisome dynamics. We could demonstrate that 
under physiological conditions peroxisomes have a half-life of approximately two days and 
are primarily degraded by an autophagy-related mechanism. In addition, we have shown that 
peroxisomes display an age-related heterogeneity regarding their matrix protein import 
competence. Moreover, our data indicate that peroxisomes generally multiply by growth and 
non-symmetrical fission. Finally, we provided evidence that the peroxisomal membrane 
proteins Pex3p and Pex16p have a much higher turnover rate than matrix proteins and are 
degraded in a proteasome-dependent manner. The sum of these findings prompted us to 
propose a hypothetical model regarding a potential quality control system that regulates the 
peroxisomal life cycle. Considering the importance of maintaining a healthy peroxisomal 
population, the existence of such a quality control is very likely. In brief, we propose that 
proteins present on the peroxisomal membrane are continuously degraded by the proteasome, 
and from the moment the peroxisome loses its matrix import competence, the organelle is 
targeted for autophagic degradation. Given the applicability of our cell model to analyze 
SUMMARY 
132 
 
different aspects of both peroxisome biogenesis and degradation, we can conclude that our 
cell model is an attractive tool to further investigate peroxisome dynamics. 
 
In the second part of this thesis, we report the detailed clinical follow-up of a patient who was 
diagnosed with the cerebro-hepato-renal syndrome of Zellweger. Mutation analysis revealed a 
novel deletional frameshift mutation in exon 3 of PEX14, a gene encoding a central 
component of the peroxisomal matrix protein import machinery. As this patient represents the 
second case of Zellweger syndrome caused by a defect in PEX14, the study of this patient 
contributes to a better understanding of the clinical picture associated with PEX14 gene 
mutations. 
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SAMENVATTING 
Peroxisomen zijn celorganellen die een belangrijke rol vervullen in het metabolisme van 
nagenoeg alle eukaryote organismen. Het belang van peroxisomen voor de mens wordt 
beklemtoond door het bestaan van verscheidene erfelijke aandoeningen. Deze ziekten worden 
ingedeeld in (i) peroxisoombiogenesestoornissen die gekenmerkt worden door de volledige 
afwezigheid van functionele peroxisomen en (ii) peroxisomale enzym-deficiënties die 
veroorzaakt worden door een defect in één enkel peroxisomaal eiwit. Gedurende de voorbije 
decennia is er heel wat onderzoek verricht naar de metabole functies van peroxisomen en de 
moleculaire aspecten van peroxisoombiogenese. Onze kennis betreffende de moleculaire 
mechanismen van peroxisoomafbraak in zoogdiercellen is echter eerder beperkt. De 
voornaamste reden hiervoor is het gebrek aan een geschikt studiemodel. In dit onderzoek 
werd daarom als doel vooropgesteld een celmodel te ontwikkelen dat geschikt is om 
peroxisoomafbraak op moleculair niveau en onder fysiologische omstandigheden te 
bestuderen in zoogdiercellen. 
 
Tijdens dit project zijn we erin geslaagd een geschikt studiemodel te ontwikkelen door 
gebruik te maken van de HaloTag technologie. Dit model is gebaseerd op een in vivo 
pulse-labeling strategie die ons toelaat om peroxisoompopulaties die worden aangemaakt 
binnen verschillende tijdsvensters te visualiseren binnen eenzelfde cel. Met behulp van dit 
systeem hebben we interessante conclusies kunnen trekken aangaande een aantal dynamische 
aspecten van peroxisomen. Zo hebben we ondermeer kunnen aantonen dat peroxisomen onder 
basale condities een halfwaardetijd bezitten van ongeveer twee dagen en dat ze voornamelijk 
worden afgebroken door een autofagie-gerelateerd mechanisme. Daarnaast is er uit onze 
experimenten gebleken dat deze celorganellen een leeftijdsgebonden heterogeniteit vertonen 
wat hun importcapaciteit voor nieuw-gesynthetiseerde matrixeiwitten betreft. Onze data 
hebben eveneens aangetoond dat peroxisomen hun matrixinhoud niet altijd evenredig 
verdelen over de dochterorganellen. Ten slotte hebben we vastgesteld dat de peroxisomale 
membraaneiwitten Pex3p en Pex16p worden afgebroken op een proteasoom-afhankelijke 
manier en een veel hogere turnover vertonen dan matrixproteïnen. Op basis van deze 
observaties hebben we een hypothese geformuleerd met betrekking tot mogelijke 
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kwaliteitscontrolemechanismen die kunnen optreden tijdens de levenscyclus van een 
peroxisoom. Kort samengevat postuleren we dat overbodige en/of dysfunctionele 
peroxisomale membraanproteïnen continu worden afgebroken door het proteasoom en dat – 
op het ogenblik dat een peroxisoom zijn importcompetentie voor matrixproteïnen verliest – 
het organel ‘gemerkt’ wordt voor afbraak door autofagie. De bruikbaarheid van ons celmodel 
om verschillende facetten van zowel peroxisoombiogenese als peroxisoomafbraak te 
ontrafelen, maakt ons studiemodel tot een attractief systeem om peroxisoomdynamiek verder 
te onderzoeken. 
 
In het tweede deel van deze thesis rapporteren we de gedetailleerde klinische follow-up van 
een patiënt die gediagnosticeerd werd met het cerebro-hepato-renaal syndroom van 
Zellweger. Mutatie-analyse heeft een nieuwe frameshift mutatie in het PEX14 gen aan het 
licht gebracht. Dit gen codeert voor een centrale component in het importsysteem van 
peroxisomale matrixproteïnen. Omdat deze casus slechts het tweede geval beschrijft van een 
Zellweger patiënt met een defect in PEX14, draagt deze studie bij tot een betere kijk op het 
klinisch beeld dat geassocieerd is met mutaties in het PEX14 gen. 
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